CA2502285A1 - Cardiolipin molecules and method of synthesis - Google Patents
Cardiolipin molecules and method of synthesis Download PDFInfo
- Publication number
- CA2502285A1 CA2502285A1 CA002502285A CA2502285A CA2502285A1 CA 2502285 A1 CA2502285 A1 CA 2502285A1 CA 002502285 A CA002502285 A CA 002502285A CA 2502285 A CA2502285 A CA 2502285A CA 2502285 A1 CA2502285 A1 CA 2502285A1
- Authority
- CA
- Canada
- Prior art keywords
- cardiolipin
- composition
- acid
- liposome
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 title claims abstract description 132
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000003786 synthesis reaction Methods 0.000 title description 20
- 230000015572 biosynthetic process Effects 0.000 title description 17
- -1 2-O- protected glycerol Chemical class 0.000 claims abstract description 82
- 239000002502 liposome Substances 0.000 claims abstract description 64
- 239000013543 active substance Substances 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 22
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 22
- 150000008300 phosphoramidites Chemical class 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 claims abstract description 14
- 239000000194 fatty acid Substances 0.000 claims abstract description 14
- 239000003446 ligand Substances 0.000 claims abstract description 7
- 230000008685 targeting Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 129
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- 239000003377 acid catalyst Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000002577 cryoprotective agent Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 2
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 claims description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 2
- 208000031295 Animal disease Diseases 0.000 claims description 2
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 2
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 claims 1
- XIIAYQZJNBULGD-LDHZKLTISA-N cholestane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XIIAYQZJNBULGD-LDHZKLTISA-N 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 239000010452 phosphate Substances 0.000 abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 abstract description 5
- 238000012801 analytical assay Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 239000002253 acid Substances 0.000 description 75
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 229910003873 O—P—O Inorganic materials 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 229910052681 coesite Inorganic materials 0.000 description 29
- 229910052906 cristobalite Inorganic materials 0.000 description 29
- 229910052682 stishovite Inorganic materials 0.000 description 29
- 229910052905 tridymite Inorganic materials 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 101150041968 CDC13 gene Proteins 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 239000012267 brine Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 229910020169 SiOa Inorganic materials 0.000 description 13
- 235000021317 phosphate Nutrition 0.000 description 13
- 239000008279 sol Substances 0.000 description 13
- 239000006188 syrup Substances 0.000 description 13
- 235000020357 syrup Nutrition 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 229910017974 NH40H Inorganic materials 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- UDIPIOHLDFSMLR-UHFFFAOYSA-N 2-phenylmethoxypropane-1,3-diol Chemical compound OCC(CO)OCC1=CC=CC=C1 UDIPIOHLDFSMLR-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 150000003536 tetrazoles Chemical class 0.000 description 7
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000000865 phosphorylative effect Effects 0.000 description 6
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 241000894007 species Species 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- OQQOAWVKVDAJOI-VWLOTQADSA-N 1,2-dilauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-VWLOTQADSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- LWCIBYRXSHRIAP-SNVBAGLBSA-N (2r)-3-phenylmethoxypropane-1,2-diol Chemical compound OC[C@@H](O)COCC1=CC=CC=C1 LWCIBYRXSHRIAP-SNVBAGLBSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QAJJXHRQPLATMK-UHFFFAOYSA-N 4,5-dichloro-1h-imidazole Chemical compound ClC=1N=CNC=1Cl QAJJXHRQPLATMK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- ZBBUFYIXSWZOIF-UHFFFAOYSA-N 1-methyl-1h-imidazol-1-ium;perchlorate Chemical compound OCl(=O)(=O)=O.CN1C=CN=C1 ZBBUFYIXSWZOIF-UHFFFAOYSA-N 0.000 description 2
- LXCFWFXRQOXBHW-UHFFFAOYSA-N 17,20-Hexacosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCCCCCC(O)=O LXCFWFXRQOXBHW-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- MIUOBAHGBPSRKY-UHFFFAOYSA-N 5-(4-nitrophenyl)-2h-tetrazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NNN=N1 MIUOBAHGBPSRKY-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- YTFJQDNGSQJFNA-UHFFFAOYSA-N benzyl dihydrogen phosphate Chemical class OP(O)(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HXJZHJLLMIGFCM-UHFFFAOYSA-N hydroxy-imino-di(propan-2-yloxy)-$l^{5}-phosphane Chemical compound CC(C)OP(N)(=O)OC(C)C HXJZHJLLMIGFCM-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229960003418 phenoxybenzamine Drugs 0.000 description 2
- 125000006245 phosphate protecting group Chemical group 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- UNSRRHDPHVZAHH-WYTUUNCASA-N (5e,8e,11e)-icosa-5,8,11-trienoic acid Chemical compound CCCCCCCC\C=C\C\C=C\C\C=C\CCCC(O)=O UNSRRHDPHVZAHH-WYTUUNCASA-N 0.000 description 1
- LSBUIZREQYVRSY-CYJZLJNKSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 LSBUIZREQYVRSY-CYJZLJNKSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- RVEKLXYYCHAMDF-UHFFFAOYSA-N (9Z,12Z)-9,12-hexadecadienoic acid Natural products CCCC=CCC=CCCCCCCCC(O)=O RVEKLXYYCHAMDF-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KSDMISMEMOGBFU-UHFFFAOYSA-N (all-Z)-7,10,13-Eicosatrienoic acid Natural products CCCCCCC=CCC=CCC=CCCCCCC(O)=O KSDMISMEMOGBFU-UHFFFAOYSA-N 0.000 description 1
- GQVYBECSNBLQJV-QXMHVHEDSA-N (z)-tridec-2-enoic acid Chemical compound CCCCCCCCCC\C=C/C(O)=O GQVYBECSNBLQJV-QXMHVHEDSA-N 0.000 description 1
- DRUFTGMQJWWIOL-ZDUSSCGKSA-N 1,2-dihexanoyl-sn-glycerol Chemical compound CCCCCC(=O)OC[C@H](CO)OC(=O)CCCCC DRUFTGMQJWWIOL-ZDUSSCGKSA-N 0.000 description 1
- ZQBULZYTDGUSSK-KRWDZBQOSA-N 1,2-dioctanoyl-sn-glycerol Chemical compound CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC ZQBULZYTDGUSSK-KRWDZBQOSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 description 1
- CDUNJRPFBBYLSJ-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl 4-oxopentanoate Chemical compound CC(=O)CCC(=O)OC(CO)CO CDUNJRPFBBYLSJ-UHFFFAOYSA-N 0.000 description 1
- NRYJWTDALUJOIC-UHFFFAOYSA-N 1,3-diiodopropan-1-ol Chemical compound OC(I)CCI NRYJWTDALUJOIC-UHFFFAOYSA-N 0.000 description 1
- DVWXJYAOASMNBW-UHFFFAOYSA-N 1,3-diiodopropoxymethylbenzene Chemical compound ICCC(I)OCC1=CC=CC=C1 DVWXJYAOASMNBW-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- VWXFUOAKGNJSBI-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide Chemical compound C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl VWXFUOAKGNJSBI-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- KCESCYYRIVTSNC-UHFFFAOYSA-N 1-phenylmethoxypropane-1,3-diol Chemical compound OCCC(O)OCC1=CC=CC=C1 KCESCYYRIVTSNC-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N 10-Methyl-heptadecanoic acid Chemical compound CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JUIXCTTUMZKIDG-UHFFFAOYSA-N 11,12,13-trihydroxytricosane-10,14-dione Chemical compound CCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCC JUIXCTTUMZKIDG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YFEXZJKJPFNYKB-UHFFFAOYSA-N 2-(oxolan-2-yloxy)oxolane Chemical class C1CCOC1OC1OCCC1 YFEXZJKJPFNYKB-UHFFFAOYSA-N 0.000 description 1
- AWBXTNNIECFIHT-XZQQZIICSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;2-[(1r,2r,3s,4r,5r,6s)-3-( Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O AWBXTNNIECFIHT-XZQQZIICSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- UAGLPPRIWBIXQY-PXSVCXFUSA-N 2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonic acid Chemical compound C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS(O)(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C UAGLPPRIWBIXQY-PXSVCXFUSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical class OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- HQSBWLQFLLMPKC-BNFZFUHLSA-N 2E,4E-Dodecadienoic acid Chemical compound CCCCCCC\C=C\C=C\C(O)=O HQSBWLQFLLMPKC-BNFZFUHLSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
- QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
- QSIFOTQDNVCTTM-UHFFFAOYSA-N 3-methyl-1h-imidazol-3-ium;trifluoromethanesulfonate Chemical compound CN1C=CN=C1.OS(=O)(=O)C(F)(F)F QSIFOTQDNVCTTM-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- AVKOENOBFIYBSA-GUTOPQIJSA-N 4,7,10,13,16-Docosapentaenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O AVKOENOBFIYBSA-GUTOPQIJSA-N 0.000 description 1
- AVKOENOBFIYBSA-UHFFFAOYSA-N 4,7,10,13,16-Docosapentaenoic acid Natural products CCCCCC=CCC=CCC=CCC=CCC=CCCC(O)=O AVKOENOBFIYBSA-UHFFFAOYSA-N 0.000 description 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 description 1
- MOYJTNHLJBMWFK-UHFFFAOYSA-N 5-(3,5-dinitrophenyl)-2h-tetrazole Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC(C=2NN=NN=2)=C1 MOYJTNHLJBMWFK-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- ZBXNFTFKKOSPLD-UHFFFAOYSA-N 5-methylsulfanyl-2h-tetrazole Chemical compound CSC1=NN=NN1 ZBXNFTFKKOSPLD-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SKCBPEVYGOQGJN-TXICZTDVSA-N 5-phospho-beta-D-ribosylamine Chemical compound N[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O SKCBPEVYGOQGJN-TXICZTDVSA-N 0.000 description 1
- GBSVAUZPMIQVJE-OSWCZRQLSA-N 6,10,14,18-eicosatetraenoic acid Chemical compound C\C=C\CC\C=C\CC\C=C\CC\C=C\CCCCC(O)=O GBSVAUZPMIQVJE-OSWCZRQLSA-N 0.000 description 1
- OKBAWLHHZWRDBE-UHFFFAOYSA-N 6,9,12,15-hexadecatetraenoic acid Natural products OC(=O)CCCCC=CCC=CCC=CCC=C OKBAWLHHZWRDBE-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QMNAQPMXDMLOLD-UHFFFAOYSA-N 6-methyl-4-oxo-5,6-dihydrothieno[2,3-b]thiopyran-2-sulfonamide Chemical compound S1C(C)CC(=O)C2=C1SC(S(N)(=O)=O)=C2 QMNAQPMXDMLOLD-UHFFFAOYSA-N 0.000 description 1
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 description 1
- XBVROPWBQOVTLB-UHFFFAOYSA-N 7,8,9-trihydroxypentadecane-6,10-dione Chemical compound CCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCC XBVROPWBQOVTLB-UHFFFAOYSA-N 0.000 description 1
- HWRZQPDAFFQNCI-UHFFFAOYSA-N 7-hydroxy-6-(hydroxymethyl)heptane-2,5-dione Chemical compound CC(=O)CCC(=O)C(CO)CO HWRZQPDAFFQNCI-UHFFFAOYSA-N 0.000 description 1
- SGTUDMPUJCDZHD-RDQFZKTJSA-N 8,12,16,19-Docosatetraenoic acid Chemical compound CC\C=C\C\C=C\CC\C=C\CC\C=C\CCCCCCC(O)=O SGTUDMPUJCDZHD-RDQFZKTJSA-N 0.000 description 1
- SKXYWXJIOLLVCT-UHFFFAOYSA-N 8-methyl lauric acid Chemical compound CCCCC(C)CCCCCCC(O)=O SKXYWXJIOLLVCT-UHFFFAOYSA-N 0.000 description 1
- ZJYIMUUTYALQDP-UHFFFAOYSA-N 9,10,11-trihydroxynonadecane-8,12-dione Chemical compound CCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCC ZJYIMUUTYALQDP-UHFFFAOYSA-N 0.000 description 1
- RVEKLXYYCHAMDF-AOSYACOCSA-N 9,12-Hexadecadienoic acid Chemical compound CCC\C=C\C\C=C\CCCCCCCC(O)=O RVEKLXYYCHAMDF-AOSYACOCSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XSXIVVZCUAHUJO-UHFFFAOYSA-N Homo-gamma-linoleic acid Natural products CCCCCC=CCC=CCCCCCCCCCC(O)=O XSXIVVZCUAHUJO-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101001092200 Mus musculus RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- OOMXGFUBBBFWHR-UHFFFAOYSA-N O.SS Chemical compound O.SS OOMXGFUBBBFWHR-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- VJNXVAVKCZJOFQ-UHFFFAOYSA-N Phenmetrazine hydrochloride Chemical compound Cl.CC1NCCOC1C1=CC=CC=C1 VJNXVAVKCZJOFQ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 101150047344 Plaa gene Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- TWSWSIQAPQLDBP-DOFZRALJSA-N all-cis-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O TWSWSIQAPQLDBP-DOFZRALJSA-N 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 229940024544 aluminum aspirin Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- ICZOIXFFVKYXOM-YCLOEFEOSA-M cefamandole nafate Chemical compound [Na+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)C=3C=CC=CC=3)[C@H]2SC1 ICZOIXFFVKYXOM-YCLOEFEOSA-M 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940084959 cephalexin hydrochloride Drugs 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- SOELXOBIIIBLRJ-UHFFFAOYSA-M choline theophyllinate Chemical compound C[N+](C)(C)CCO.CN1C(=O)N(C)C([O-])=C2N=CN=C21 SOELXOBIIIBLRJ-UHFFFAOYSA-M 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000267 diphenadione Drugs 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- HQSBWLQFLLMPKC-UHFFFAOYSA-N dodecadienoic acid Natural products CCCCCCCC=CC=CC(O)=O HQSBWLQFLLMPKC-UHFFFAOYSA-N 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229950007285 etintidine Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- PWDGZOJXLJLQTE-UHFFFAOYSA-N hexadeca-4,8,11,14-tetraenoic acid Chemical compound CC=CCC=CCC=CCCC=CCCC(O)=O PWDGZOJXLJLQTE-UHFFFAOYSA-N 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229940065346 hydroxyprogesterone acetate Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- QSMHRTSIMKYDTO-UHFFFAOYSA-N icosa-4,8,12,16-tetraenoic acid Chemical compound CCCC=CCCC=CCCC=CCCC=CCCC(O)=O QSMHRTSIMKYDTO-UHFFFAOYSA-N 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- 229940018435 isoproterenol sulfate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229960001263 mecamylamine hydrochloride Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
- 229960002931 methacholine chloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229950008080 mioflazine Drugs 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- CHWMPPNDIBLYMB-UHFFFAOYSA-N n',n'-bis(prop-2-enyl)ethane-1,2-diamine Chemical compound NCCN(CC=C)CC=C CHWMPPNDIBLYMB-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YFYBXOIQXOOUCI-UHFFFAOYSA-N n-[[di(propan-2-yl)amino]-methoxyphosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(OC)N(C(C)C)C(C)C YFYBXOIQXOOUCI-UHFFFAOYSA-N 0.000 description 1
- ONBPLQYGTOGWFZ-UHFFFAOYSA-N n-[[di(propan-2-yl)amino]-phenylmethoxyphosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ONBPLQYGTOGWFZ-UHFFFAOYSA-N 0.000 description 1
- CRONOPUTNCCWQH-UHFFFAOYSA-N n-[chloro(phenylmethoxy)phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(Cl)OCC1=CC=CC=C1 CRONOPUTNCCWQH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- YPVUHOBTCWJYNQ-SLHNCBLASA-N norgesterone Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C=C)[C@@H]3[C@@H]1CC2 YPVUHOBTCWJYNQ-SLHNCBLASA-N 0.000 description 1
- 229950011191 norgesterone Drugs 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005254 oxyacyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229950005116 phenaglycodol Drugs 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 229960001753 phenformin hydrochloride Drugs 0.000 description 1
- 229960002315 phenmetrazine hydrochloride Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
- 229960003253 procainamide hydrochloride Drugs 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960002153 prochlorperazine maleate Drugs 0.000 description 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- JFNWFXVFBDDWCX-UHFFFAOYSA-N sulfisoxazole acetyl Chemical compound C=1C=C(N)C=CC=1S(=O)(=O)N(C(=O)C)C=1ON=C(C)C=1C JFNWFXVFBDDWCX-UHFFFAOYSA-N 0.000 description 1
- 229950006904 sulfisoxazole acetyl Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- SDCJNZZAOLRVCP-GTOSQJSUSA-N tetramyristoyl cardiolipin Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCC)COP(O)(=O)OCC(O)COP(O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC SDCJNZZAOLRVCP-GTOSQJSUSA-N 0.000 description 1
- TWHQNHQPSCPQNY-WVRHUKEESA-N tetraoleyl cardiolipin Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)COP(O)(=O)OCC(O)COP(O)(=O)OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC TWHQNHQPSCPQNY-WVRHUKEESA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid group Chemical group C(\C(\C)=C\C)(=O)O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- APXSAEQXOXTDAM-AATRIKPKSA-N trans-10-pentadecenoic acid Chemical compound CCCC\C=C\CCCCCCCCC(O)=O APXSAEQXOXTDAM-AATRIKPKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- XJGONMZLEDGBRM-UHFFFAOYSA-M tridihexethyl chloride Chemical compound [Cl-].C=1C=CC=CC=1C(O)(CC[N+](CC)(CC)CC)C1CCCCC1 XJGONMZLEDGBRM-UHFFFAOYSA-M 0.000 description 1
- 229960001205 tridihexethyl chloride Drugs 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O- protected glycerol, with a phosphoramidite reagent or a phosphate triester t o produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseas es or in diagnostic and/or analytical assays. Liposomes can also include ligand s for targeting a particular cell type or specific tissue.
Description
CARDIOLIPIN MOLECULES AND METHODS OF SYNTHESIS
FIELD OF THE INVENTION
[0001] This invention pertains to novel synthetic methods for preparing cardiolipin analogs/variants, and compositions containing them. The invention also pertains to liposome formulations or complexes or emulsions containing active agents or drugs and their use in the treatment of diseases in humans and animals.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] This invention pertains to novel synthetic methods for preparing cardiolipin analogs/variants, and compositions containing them. The invention also pertains to liposome formulations or complexes or emulsions containing active agents or drugs and their use in the treatment of diseases in humans and animals.
BACKGROUND OF THE INVENTION
[0002] Liposomal formulations have the capacity to increase the solubility of hydrophobic drugs in aqueous splution. They often reduce the side effects associated with drug therapy and they provide flexible tools for developing new formulations of active agents.
[0003] Liposomes are commonly prepared from natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, and phosphatidylinositol. Anionic phospholipids, such as phosphatidyI
glycerol and bardiolipin, can be added to generate a net negative surface charge that provides for colloid stabilization. These components are often purified from natural sources and in some cases they can be chemically synthesized.
glycerol and bardiolipin, can be added to generate a net negative surface charge that provides for colloid stabilization. These components are often purified from natural sources and in some cases they can be chemically synthesized.
[0004] The nature and density of the surface charge of liposomes influences stability, kinetics, biodistribution, and interaction with, and.uptake by target cells.
Liposome surface charge also influences the tendency for liposomes to aggregate, which makes liposomes difficult to work with and affects uptake by target cells. In this respect, liposomes with a neutral surface charge have the highest tendency to aggregate, but are less likely to be cleared by cells of the reticuloendothelial system (RES) after systemic administration.
Negatively charged liposomes, on the other hand, exhibit reduced aggregation and increased stability, but exhibit non-specific cellular uptake in vivo. Thus, it has been suggested that a small amount of negatively charged lipids may stabilize neutral liposomes against an aggregation-dependent uptake mechanism (see, e.g., Drumrnond et al., Pharm.
Rev, 51, 691-743 (1999)).
[OOOSj Cardiolipin (also known as diphosphatidyl glycerol) constitutes a class of complex anionic phospholipids that is typically purified from cell membranes of tissues associated with high metabolic activity, including the mitochondria of heart and skeletal muscles. The negative surface charge of cardiolipin, therefore, stabilizes liposomes against aggregation-dependent uptake, as discussed above. In animal tissues and mitochondria, cardiolipin contains up to 90% of linoleic acid (18:2). Yeast cardiolipin differs in having more oleic (18:1) and palmitoleic (16:1) fatty acids, while the bacterial lipid contains SUBSTITUTE SHEET (RULE 26) saturated and monoenoic fatty acids with 14 to 18 carbons. However caxdiolipin having shortchain fatty acids are unknown till now. The potential effects of the length and nature of cardiolipin fatty acid chains (i.e., saturated or unsaturated) on liposome aggregation have not been elucidated.
[0006] Methods for synthesizing cardiolipin comprising short fatty acid chains ("short chain cardiolipin") have not yet been described. Generally, known methodologies for synthesizing cardiolipin are mainly divided in two groups: (a) coupling the primary hydroxyl groups of a 2-protected glycerol with 1,2-diacyl-sh-glycerol using a phosphorylating agent and (b) condensation at both primary hydroxyl groups of a 2-protected glycerol with phosphatidic acid in the presence of 2,4,6-txiisopropylbenzenesulfonylchloride (TPS) or pyridine (see, e.g., Ramirez et al., Synthesis, ' 11, 769-770 (1976), Duralski et al., Tetrahed~~o~~Lett. 39, 1607-1610 (1998), Sounders and Schwarz, J. Am. Chenz. Soc. 88, 3844-3847 (1966), Mishina et al., Bioorg.
Khim. 11, 992-994 (1985), and Stepanov et al., Zh. Org., Khim. 20, 985-988 (x984)).
Cardiolipin has also ' been generated via a reaction between the silver salt of diacylglycerophosphoric acid benzyl ester with 1,3-diiodopropanol benzyl ether or 1,3-diiodopropanol t-butyl ether (see, e.g., De Haas et al., Biochinz. Biophys. Acta,116, 114-124 (1966) and moue et al., Chem. Plaa~m.
Bull. 11,1150-1156 (1963)). Although the schemes were suitable for the preparation of small quantities of cardioiipin, those were unattractive for the routine preparation of larger quantities due to the many steps involved, the requirement for careful purification of intermediates and the use of highly photosensitive silver salt derivatives and unstable iodo intermediates.
[0007] Phosphate triesters and phosphoramidite esters have been used extensively in nucleic acid synthesis to form phosphate linkages, and to a lesser extent in phospholipid synthesis (see, e.g., Browne et al., J. Chem. Soc. Pef~ki~ T~ahs, 1, 653-657 (2000)). In this respect, Browne et al., supra, describes the preparation of phospholipid analogs, particularly phosphorylcholine analogs, using phosphoranaidite methodologies. The phosphatidylinositols Ptdlns(4,5)P2 and PtdIns(3,4,5)P3, and derivatives thereof, have been prepared using a variety of phosphoramidite reagents, including N, N-diisopropylphosphoramidite (see, e.g., Watanabe et al., Tet~al2edrof~ Lett.
35, 123-124 (1994)), difluorenyl phosphoramidite (see, e.g., Watanabe et al., Tet~ ahed~on Lett. 38, 7407-7410 (1997)), and a reagent produced by reacting a diacylglycerol with (benzyloxy)(N, N-diisopropylamino)chlorophosphine (see, e.g., Chen et al., J.
Org. Claem., 61, 6305-6312 (1996) and Prestwich et al., Acc. Chem. Res., 29, 503-513 (1996)). In addition, phosphotriester analogs of PtdIns(4,5)Pa and Ptdlns(3,4,5)P3 have been prepared utilizing the phosphoramidite reagent 2-cyano-ethyl N, N, N, N-tetraisopropylphosphorodiamidite (see, e.g., Gu et al., J. Or~g. ChenZ, 61, (1996)). Moreover, Muralcama. et al., J. Or~g. C~em, 6~, d48-6S1 (1999) describe tlxe synthesis of phosphatidyl glycerol from 2,S-diben~yl-D-manuitol utilizing methyl tetraisopropylphosphorodiamidite as a phosphorylating agent. The use ofphosphate triesters and phosphoramidite esters in preparing phospholipids such as caxdiolipin, particularly cardiolipin species having varying fatty acid chain lengths, however, is not well established.
[0008 New synthetic methods are needed that can be used to prepare large quantities of saturated and unsaturated cardioiipin species having varying fatty acid chain length, particularly "shoe chain cardiolipins". Such methods would increase the availability of a wider variety of cardioiipin species and would diversify the lipids available for development of new liposomal formulations containing active agents, which will have more defined compositions than those currently available.
[0009] The invention provides such methods and compositions. These and other advantages of the invention, as well as additional inventive features, will be evident from 1 S the description of the invention provided herein.
BRIEF SUI~~MARY OF THE INVENTION
[0010] The invention provides novel synthetic methodologies for preparing cardiolipin.
having varying fatty acids and/or alkyl chains with varying length and saturation/unsaturation. The methods comprises of {a) reacting an optically pure 1,2-0-diacyl-sfz-glycerol or 1,2-O-dialkyl-sr~-glycerol with one or more phosphoramidite xeagent(s) or one yr more phosphate triester(s), (b) coupling the product of (a) with a 2-protected glycerol, wherein a protected cardioiipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. The invention also provides a method for preparing cardiolipin having varying fatty acid chain lengths comprising (a) 2S reacting a 2-O-protected glycerol with one or more phosphoramidite reagents, wherein a phosphoxylating agent is produced, (b) reacting the phosphorylating agent witlx an optically pure 1,2-O-diacyl-sh-glycerol or 1,2-O-dialkyl-sn-glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared.
[0011.] The cardiolipin prepared by the present methods can be incozporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 depicts tlxe general sia7xcture of caxdiolipin.
[0013] Figure 2 depicts one sclxeme for synthesizing cardiolipin.
[0014] Figure 3 depicts an alternative synthetic scheme for cardiolipin.
[0015 Figure 4 depicts an alternative syntl2etic scheme for eardiolipin.
[0016] Figure 5 depicts an alternative synthetic scheme for cardiolipin.
[001] Figure 6 depicts alz alternative synthetic scheme for cardiolipin ether analogs.
[OOIBJ Figure 7 depicts an alternative synthetic scheme fox cardiolipizz ether analogs.
DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention describes methods for the synthesis of cardiolipin variants and analogs having the general formulas I, II, and III, as well as compositions containing such variants and analogs.
Rl C--O 'O'C'.~1 O
Rz C-O O"C'Rz O O~T O
O-P'O~O-P-O
O-X~ O'~
I
Rx O-Rl R2 O_Rz II
RI Y1 y.i'.R1 Rz_....yz Yz"'Rz O
R3---O--p-O-.R5,~R5_"'O""p""'.O.'_R3 O~- O"X-t-III
In Formula In, Y~ andYz are the same or different and are -O-C(O)-, -O-, -S~, NT~-C(O)-or the like. Tn Formulas I, II and III, R~ and Rz are the same or different and are T-I, saturated andlor iuisaturated alkyl group, preferably a Cato C34 saturated andlor unsaturated allcyl group. Tn Formula III, R3 is (CH2)n anal n = 0 -- 15. Tn Formula III, Ri. is hydrogen, alkyl, substituted alkyl, cycloall~yl, substituted cycloalltyl, a peptide, dipeptide, polypeptide, protein, carbohydrate (such as glucose, mannose, galactose, polysaccharide and the lilce),.
h.eterocyclic, nucleoside, polynucieotide and the lilce. Tn Formula III, RS is a linlcer, 'which may (or may not be) added in the na.olecule depending on the need and applications.
Ptinted:l6-(~~-2004 DESCPAMD EP03749443.2 - PCTUS 03 27806 However, where added, RS can comprise alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, polyalkyloxy (such as pegylated ether of containing from about 1 to 500 alkyloxymers (and can have at least about 10 alkyloxy mers, such as at least about 50 alkyloxy mers or at least about 100 alkyloxy mers, such as at least about 200 alkyloxy mers 5 or at least about 300 alkyloxy mers or at least about 400 alkyloxy mers), substituted polyalkyloxy and the like), a peptide, dipeptide, polypeptide, protein, carbohydrate such as glucose, mannose, galactose, polysaccharides and the like. In Formulas I, II
and III, X is hydrogen or a non-toxic cation, preferably ammonium, sodium, potassium, calcium, barium ion and the like.
(0020] The term'alkyl'encompasses saturated or unsaturated straight-chain and branched-chain hydrocarbon moieties. The term"substituted alkyl'comprises alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy (of a lower alkyl group), mercapto (of a lower alkyl group), cycloalkyl, substituted cyeloalkyl, halogen, cyano, nitro, amino, amido, imino, thio, -C(O)H, acyl, oxyacyl, carboxyl, and the like.
[0021) In the most preferred embodiment Y, and Y2 in Formula III are--~C(O)-or -O-.
R3 is most preferably is CH2. Also, in Formulas I, II, and III, R, and R2 are the same and are a C2 to Ci3 saturated andlor unsaturated alkyl group, more preferably between 4 and 14 carbon atoms (such as between about G and 12 carbon atoms). X most preferably is hydrogen or ammonium ion. In the absence of linker (RS), it gives the general structure of cardiolipin (Figure I).
(0022] The invention provides a method for preparing cardiolipin or an analogue thereof of Formulas I, II, or III, comprising reacting an alcohol of the formula VIII with one or more phosphoramidite reagents and 2-O-protected glycerol or 2-O-subsituted glycerol VI in the presence of an acid catalyst.
YyRi OY Y~.RZ
HO.~OH HO-R3 VI VIII
Y in formula VI is a hydroxyl protecting group, preferably alkyl group or the like, or a silyl protecting group. In Formula VIII, Ri, Rz, R3, Y,, and Y2, can be as indicated above with respect to Formulas I, II, or III. In accordance with the inventive method, the acid catalyst can be any suitable catalyst that can facilitate the reaction. Examples of such catalysts include 4,5-dichloroimidazole, IH-tetrazole, 5-(4-nitrophenyl)-1H tetrazole, 5-(3,5-dinitrophenyl)-1H-tetrazole, N-methylimidazolium triflate, and N-methylimidazolium perchlorate, 4,5-dicyanoimidazole, 5-ethylthio-iN-tetrazole, and 5-methylthio-1H tetrazole.
Liposome surface charge also influences the tendency for liposomes to aggregate, which makes liposomes difficult to work with and affects uptake by target cells. In this respect, liposomes with a neutral surface charge have the highest tendency to aggregate, but are less likely to be cleared by cells of the reticuloendothelial system (RES) after systemic administration.
Negatively charged liposomes, on the other hand, exhibit reduced aggregation and increased stability, but exhibit non-specific cellular uptake in vivo. Thus, it has been suggested that a small amount of negatively charged lipids may stabilize neutral liposomes against an aggregation-dependent uptake mechanism (see, e.g., Drumrnond et al., Pharm.
Rev, 51, 691-743 (1999)).
[OOOSj Cardiolipin (also known as diphosphatidyl glycerol) constitutes a class of complex anionic phospholipids that is typically purified from cell membranes of tissues associated with high metabolic activity, including the mitochondria of heart and skeletal muscles. The negative surface charge of cardiolipin, therefore, stabilizes liposomes against aggregation-dependent uptake, as discussed above. In animal tissues and mitochondria, cardiolipin contains up to 90% of linoleic acid (18:2). Yeast cardiolipin differs in having more oleic (18:1) and palmitoleic (16:1) fatty acids, while the bacterial lipid contains SUBSTITUTE SHEET (RULE 26) saturated and monoenoic fatty acids with 14 to 18 carbons. However caxdiolipin having shortchain fatty acids are unknown till now. The potential effects of the length and nature of cardiolipin fatty acid chains (i.e., saturated or unsaturated) on liposome aggregation have not been elucidated.
[0006] Methods for synthesizing cardiolipin comprising short fatty acid chains ("short chain cardiolipin") have not yet been described. Generally, known methodologies for synthesizing cardiolipin are mainly divided in two groups: (a) coupling the primary hydroxyl groups of a 2-protected glycerol with 1,2-diacyl-sh-glycerol using a phosphorylating agent and (b) condensation at both primary hydroxyl groups of a 2-protected glycerol with phosphatidic acid in the presence of 2,4,6-txiisopropylbenzenesulfonylchloride (TPS) or pyridine (see, e.g., Ramirez et al., Synthesis, ' 11, 769-770 (1976), Duralski et al., Tetrahed~~o~~Lett. 39, 1607-1610 (1998), Sounders and Schwarz, J. Am. Chenz. Soc. 88, 3844-3847 (1966), Mishina et al., Bioorg.
Khim. 11, 992-994 (1985), and Stepanov et al., Zh. Org., Khim. 20, 985-988 (x984)).
Cardiolipin has also ' been generated via a reaction between the silver salt of diacylglycerophosphoric acid benzyl ester with 1,3-diiodopropanol benzyl ether or 1,3-diiodopropanol t-butyl ether (see, e.g., De Haas et al., Biochinz. Biophys. Acta,116, 114-124 (1966) and moue et al., Chem. Plaa~m.
Bull. 11,1150-1156 (1963)). Although the schemes were suitable for the preparation of small quantities of cardioiipin, those were unattractive for the routine preparation of larger quantities due to the many steps involved, the requirement for careful purification of intermediates and the use of highly photosensitive silver salt derivatives and unstable iodo intermediates.
[0007] Phosphate triesters and phosphoramidite esters have been used extensively in nucleic acid synthesis to form phosphate linkages, and to a lesser extent in phospholipid synthesis (see, e.g., Browne et al., J. Chem. Soc. Pef~ki~ T~ahs, 1, 653-657 (2000)). In this respect, Browne et al., supra, describes the preparation of phospholipid analogs, particularly phosphorylcholine analogs, using phosphoranaidite methodologies. The phosphatidylinositols Ptdlns(4,5)P2 and PtdIns(3,4,5)P3, and derivatives thereof, have been prepared using a variety of phosphoramidite reagents, including N, N-diisopropylphosphoramidite (see, e.g., Watanabe et al., Tet~al2edrof~ Lett.
35, 123-124 (1994)), difluorenyl phosphoramidite (see, e.g., Watanabe et al., Tet~ ahed~on Lett. 38, 7407-7410 (1997)), and a reagent produced by reacting a diacylglycerol with (benzyloxy)(N, N-diisopropylamino)chlorophosphine (see, e.g., Chen et al., J.
Org. Claem., 61, 6305-6312 (1996) and Prestwich et al., Acc. Chem. Res., 29, 503-513 (1996)). In addition, phosphotriester analogs of PtdIns(4,5)Pa and Ptdlns(3,4,5)P3 have been prepared utilizing the phosphoramidite reagent 2-cyano-ethyl N, N, N, N-tetraisopropylphosphorodiamidite (see, e.g., Gu et al., J. Or~g. ChenZ, 61, (1996)). Moreover, Muralcama. et al., J. Or~g. C~em, 6~, d48-6S1 (1999) describe tlxe synthesis of phosphatidyl glycerol from 2,S-diben~yl-D-manuitol utilizing methyl tetraisopropylphosphorodiamidite as a phosphorylating agent. The use ofphosphate triesters and phosphoramidite esters in preparing phospholipids such as caxdiolipin, particularly cardiolipin species having varying fatty acid chain lengths, however, is not well established.
[0008 New synthetic methods are needed that can be used to prepare large quantities of saturated and unsaturated cardioiipin species having varying fatty acid chain length, particularly "shoe chain cardiolipins". Such methods would increase the availability of a wider variety of cardioiipin species and would diversify the lipids available for development of new liposomal formulations containing active agents, which will have more defined compositions than those currently available.
[0009] The invention provides such methods and compositions. These and other advantages of the invention, as well as additional inventive features, will be evident from 1 S the description of the invention provided herein.
BRIEF SUI~~MARY OF THE INVENTION
[0010] The invention provides novel synthetic methodologies for preparing cardiolipin.
having varying fatty acids and/or alkyl chains with varying length and saturation/unsaturation. The methods comprises of {a) reacting an optically pure 1,2-0-diacyl-sfz-glycerol or 1,2-O-dialkyl-sr~-glycerol with one or more phosphoramidite xeagent(s) or one yr more phosphate triester(s), (b) coupling the product of (a) with a 2-protected glycerol, wherein a protected cardioiipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. The invention also provides a method for preparing cardiolipin having varying fatty acid chain lengths comprising (a) 2S reacting a 2-O-protected glycerol with one or more phosphoramidite reagents, wherein a phosphoxylating agent is produced, (b) reacting the phosphorylating agent witlx an optically pure 1,2-O-diacyl-sh-glycerol or 1,2-O-dialkyl-sn-glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared.
[0011.] The cardiolipin prepared by the present methods can be incozporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 depicts tlxe general sia7xcture of caxdiolipin.
[0013] Figure 2 depicts one sclxeme for synthesizing cardiolipin.
[0014] Figure 3 depicts an alternative synthetic scheme for cardiolipin.
[0015 Figure 4 depicts an alternative syntl2etic scheme for eardiolipin.
[0016] Figure 5 depicts an alternative synthetic scheme for cardiolipin.
[001] Figure 6 depicts alz alternative synthetic scheme for cardiolipin ether analogs.
[OOIBJ Figure 7 depicts an alternative synthetic scheme fox cardiolipizz ether analogs.
DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention describes methods for the synthesis of cardiolipin variants and analogs having the general formulas I, II, and III, as well as compositions containing such variants and analogs.
Rl C--O 'O'C'.~1 O
Rz C-O O"C'Rz O O~T O
O-P'O~O-P-O
O-X~ O'~
I
Rx O-Rl R2 O_Rz II
RI Y1 y.i'.R1 Rz_....yz Yz"'Rz O
R3---O--p-O-.R5,~R5_"'O""p""'.O.'_R3 O~- O"X-t-III
In Formula In, Y~ andYz are the same or different and are -O-C(O)-, -O-, -S~, NT~-C(O)-or the like. Tn Formulas I, II and III, R~ and Rz are the same or different and are T-I, saturated andlor iuisaturated alkyl group, preferably a Cato C34 saturated andlor unsaturated allcyl group. Tn Formula III, R3 is (CH2)n anal n = 0 -- 15. Tn Formula III, Ri. is hydrogen, alkyl, substituted alkyl, cycloall~yl, substituted cycloalltyl, a peptide, dipeptide, polypeptide, protein, carbohydrate (such as glucose, mannose, galactose, polysaccharide and the lilce),.
h.eterocyclic, nucleoside, polynucieotide and the lilce. Tn Formula III, RS is a linlcer, 'which may (or may not be) added in the na.olecule depending on the need and applications.
Ptinted:l6-(~~-2004 DESCPAMD EP03749443.2 - PCTUS 03 27806 However, where added, RS can comprise alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, polyalkyloxy (such as pegylated ether of containing from about 1 to 500 alkyloxymers (and can have at least about 10 alkyloxy mers, such as at least about 50 alkyloxy mers or at least about 100 alkyloxy mers, such as at least about 200 alkyloxy mers 5 or at least about 300 alkyloxy mers or at least about 400 alkyloxy mers), substituted polyalkyloxy and the like), a peptide, dipeptide, polypeptide, protein, carbohydrate such as glucose, mannose, galactose, polysaccharides and the like. In Formulas I, II
and III, X is hydrogen or a non-toxic cation, preferably ammonium, sodium, potassium, calcium, barium ion and the like.
(0020] The term'alkyl'encompasses saturated or unsaturated straight-chain and branched-chain hydrocarbon moieties. The term"substituted alkyl'comprises alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy (of a lower alkyl group), mercapto (of a lower alkyl group), cycloalkyl, substituted cyeloalkyl, halogen, cyano, nitro, amino, amido, imino, thio, -C(O)H, acyl, oxyacyl, carboxyl, and the like.
[0021) In the most preferred embodiment Y, and Y2 in Formula III are--~C(O)-or -O-.
R3 is most preferably is CH2. Also, in Formulas I, II, and III, R, and R2 are the same and are a C2 to Ci3 saturated andlor unsaturated alkyl group, more preferably between 4 and 14 carbon atoms (such as between about G and 12 carbon atoms). X most preferably is hydrogen or ammonium ion. In the absence of linker (RS), it gives the general structure of cardiolipin (Figure I).
(0022] The invention provides a method for preparing cardiolipin or an analogue thereof of Formulas I, II, or III, comprising reacting an alcohol of the formula VIII with one or more phosphoramidite reagents and 2-O-protected glycerol or 2-O-subsituted glycerol VI in the presence of an acid catalyst.
YyRi OY Y~.RZ
HO.~OH HO-R3 VI VIII
Y in formula VI is a hydroxyl protecting group, preferably alkyl group or the like, or a silyl protecting group. In Formula VIII, Ri, Rz, R3, Y,, and Y2, can be as indicated above with respect to Formulas I, II, or III. In accordance with the inventive method, the acid catalyst can be any suitable catalyst that can facilitate the reaction. Examples of such catalysts include 4,5-dichloroimidazole, IH-tetrazole, 5-(4-nitrophenyl)-1H tetrazole, 5-(3,5-dinitrophenyl)-1H-tetrazole, N-methylimidazolium triflate, and N-methylimidazolium perchlorate, 4,5-dicyanoimidazole, 5-ethylthio-iN-tetrazole, and 5-methylthio-1H tetrazole.
Preferred catalysts are 4,5-dichloroimidazole orlH tetrazole. In accordance with the inventive method, the coupling phosphoranudites can have formu.l.a IV or V:
Y_ ,~x Y Y
~--'N P ~N...P_N~
Cl OX
IV v [0023] In another embodiment, the invention provides a method for preparing cardiolipin or an analogue thereaf of formulas I, II, or III; comprising reacting 2-O
protected glycerol with one or more phosphotriesters in the presence of pyridinium tribromide. Preferred phosphotr~iesters can be produced by reacting an alcohol of formula VIII with phosphoramidite of general formula VII.
~--N--P-OX
OX
VII
[0024] X in Formutas IV, V, ox VII is a phosphate protecting group, preferably a benzyl group or 2-cyanoethyl or silyl group. Other examples of suitable protecting groups include allcyl phosphates including ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2-trichloroethyi, 2,2,2-tribrornoethyl, 2,2,2-trifluoxoethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
[0025] A general sequence of reactions for the synthesis of compound of invention is illustrated in Figures 2 & 3.The present invention provides a method for preparing cardiolipin I having varying fatty acid chain lengths comprising (a) reacting an optically pure 1,2-O-diacyl s~-glycerol 2 with one or more phosphorarx~idite reagent(s)of the general formula IV (figure 2) or V (figure 3) (b) coupling the product of (a) 3 with a 2-O-protected glycerol VI in a chlorinated solvent (for example dichloramethane, chloroform or like) followed by oxidation with m-chloroperoxybenzoic acid (m-CPBA) results in the production of a protected cardiolipin 4. Thereafter, deprotecting the protected cardiolipin followed by conversion to ammonium salt will result in the production of cardiolipin 1 (ammonium salt).
[0026] For reaction with optically pure 1,2-O-diacyl sre-glycerol 2, any suitable phasphoramidite reagent or methodology may be used, such as is described in, for example Browne et al., supra. Bxasnples of suitable phosphoramidite reagents include (benzyloxy)(N, N diisopropylamino)chlorophosphine (see, e.g., Prestwich et al.
J. .Ntrn.
Chem. hoc. 1.991,113, 1822-1.825), benzyloxybis (diisopropylamino) phosphine (see, e.g., Dreef et al. Tetr~ahednon Lett. 1988, 29, 6513-6516), 2-cyanoethyl-N, N, N, .N
tetraisopropylphosphoramidite (see, e.g., Browne et al. J. Chem. Soc. Per~kir~
Tans. 1. 2000, 653-657.), (2-cyanoethyl)(N,~V diisopropylaznino)chlorophosphine (see, e.g., Prestwich et al. J. O~g. Chem. 1998, 63, 6511-6522), difluorenyl diisopropylphosphoramidite (see, e.g., Watanabe et al. Tet~ahed~on Lett. 1997, 3S, 7407-7410), methyl-N, N, N, N
tetraisopropylphosphorodiamidite (see, e.g., Murakami et al. J. Or~g. Chern.
1999, 64, 648-651), dimethyl N, N-diisopropylphosphoraznidite (see, e.g., Watanabe et al.
Tetr~ahedr~on Lett. 1993, 34, 497-500), dibenzyl diisopropylphosphoramidite (see, e.g., Watanabe et al.
Tet~ahedr~on Lett. 2000, 41, 8509-8512), di-te~t"butyl-N,N
diisopropylphosphoramidite (see, e.g., Lindberg et aI. J. Or~g. Chew. 2002, 67, I94-199.), 2-(diphenylmethylsilyl)ethyl-N, N, N, N tetraisopropylphosphoramidite (see, e.g., Chevallier et al. Or g Lett. 2000, 2, 1859-x861), (N-trifluoroacetylamino) butyl and (N-trifluoroacetylamino) pentyl N N, N, N
tetraisopropylphosphoramidites (see, e.g., wilk et al. J. O>"g. Chem. 1.997, 62, 6712-6713).
[0027] Another embodiment of the present invention is depicted in Figure 4. Tn this method the optically pure 1,2-O-diacyl-sn-glycerol 2 can be phosphorylated using phosphoranv.dite VII to yield phosphate triesters 5 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol ar levulinoyl-1, 3-propanediol using pyxidizuuzn perbrolnide and phosphoniuzn salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin 4. The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopxopylphosphoramidite.
(0028] In an alternative strategy set fozfih in Figure 5, the inventive method comprises (a) reacting a 2-O-protected glycerol VI with one or more phosphoramidite reagents IV or V, wherein a phosphorylating agent 6 is produced, (b) reacting the phosphorylating agent b with an optically pure 1,2-O-diacyl-srx-glycerol 2 followed by oxidation with m-CPBA, wherein a protected cardiolipin 4 is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. Suitable phosphoramidite reagents and 2-O-protected glycerols fvr use in this aspect of the izzventive method are described above.
(0029] Another embodiment of the present invention, represented in Figure 6 leads to ether azlalogs of cardioiipin, wherein the acyl groups are replaced by all~.yl chain.
Accordingly (a) 1,2-O-dialkyl-sn-glycerol 7 is treated with phosphoraznidites IV ox V
wherein a pl~osphozylating agent 8 is produced, (b) reacting the phosphorylating agent with a 2-O-protected glycerol VI followed by oxidation, wherein a protected cardiolipin 9 is produced, and (c) deprotecting the protected cardiolipin, such that the ether analog of cardiolipin 10 is produced.
[0030] Another embodiment ofthe present invention is depicted in Figure 7. In this method the optically pure I,2-O-dialkyl-stz-glycerol 7 can be phosphorylated using phosphoramidite VII to yield phosphate triestexs 11 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy I,3-propanediol or levulinoyl-I, 3-propanediol using pyridinium perbromide and phosphonium salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin ether analog 9.
The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
[0031] The invention described above is an elegant and efficient method of synthesizing cardaolipin. The routes are short and proceed in good overall yield. The deprotectaon can be accomplished by a method depending on the protecting group. For example a benzyl group can be removed by catalytic hydrogenolysis or by treatment with NaT, 2-cyanoethyl and fluorenylmethyl groups by treatment with a tertiary base such as triethylamine, a silyl group can be deprotected with fluoride ion or acidic medium, a levulinoyl group by hydrazinolysis.
[0032] The synthetic methods described herein can be modified in any suitable manner.
Fox example, phosphoramidites and phosphate esters can be prepared using a variety of acid catalysts, including 4,5-dichloroimidazole (see, e.g., Browne et al.), 5-(4-nitrophenyl)-1H
tetrazole, 5-(3,5-dinitrophenyl)-IH tetrazole, N-methylimi.dazolium traflate, and N-methylimidazolium perchlorate (see, e.g., Moriguchi et al.). Likewise, tert-butylhydroperoxide can be used as an alternative oxidant. The described methods can be further modified in any suitable manner known in the art.
[0033] The inventive method can be used to prepare cardaolipin species comprising fatty acid lalkyl chains of varying length and saturation/unsaturation. The general structure of a phospholipid fatty acid comprises a hydrocarbon chain and a carboxylic acid group. In general, the length of the fatty acid hydrocarbon chain ranges from about 2 to about 34 carbon atoms and can be saturated or unsaturated. I~owever, the carbon chain is more typically between about I2 and about 24 carbon atoms. In some embodiments, it is desirable for the hydrocarbon chain to comprise, for example, at least about 5 carbon atoms or at least about 10 carbon atoms ox even at least about 15 carbon atoms.
Typically, the length of the fatty acid hydrocarbon is less than about 24 carbon acids, such as less than.
about 24 carbon atoms, or even less than about 20 carbon atoms.
[003] The invention also provides a cardiolipin or cardaoliphl analogue prepared in accordance with the inventive method. Most preferably, the cardaolipin prepared by the inventive method comprises a short fatty acid chain (i.e., a "short chain cardiolipin"), and the invention provides a short chain cardiolipua. A short fatty acid chain comprises between about 2 and between about I4 carbon atoms, and can have between about 4 (or about 6) and about 12 carbon atoms, such as between about 8 and about 10 carbon atoms.
Alternatively, the cardiolipin produced by the inventive method can comprise a long chain fatty acid chain (i.e., a "long chain cardiolipin"). A long fatty acid chain comprises between about 14 and about 34 carbon atoms, such as between about 14 (or between about 20) and about 24 carbon atoms. The inventive method is not limited to the production of shoat or long chain cardiolipin species exclusively. Indeed, a eaxdialipin containing fatty acid/alkyl chains of intermediate length can also be prepared by the inventive method.
[U035] Phospholipid fatty acids typically are classified by the number of double and/or triple bonds in the hydrocarbon chain (i.e., unsaturation}. A saturated fatty acid does not contain any double or triple bonds, and each carbon in the chain is bound to the maximum number of hydrogen atoms. The degree of unsaturation of a fatty acid depends on the number of double or triple bonds present in tl~.e hydrocarbon chain. 1n this respect, a monounsaturated fatty acid contains one double bond, whereas a polyunsaturated fatty acid contains two or more double bonds (see, e.g., Oxford Dictionary ofBiochemistry and Moleculas~ Biology, rev. ed., A.D. Smith (ed.), Oxford University Press (2000), and .
Molecular Biology of the Cell, 3r'~ ed., B.A. Alberts (ed.), Garland Publishing, New York (I994)). The fatty acid chains of the cardiolipin are prepared by the inventive method, whether short or long, also can be saturated or unsaturated.
[0036] The described methods can be used to prepare a variety of novel cardiolipin molecules. For example, the methods can be used to pxepare cardiolipin variants in pure form containing short or long fatty acid side chains. Preferred fatty acids range from carbon chain lengths of about C2 to C34, preferably between about C~ and about Ca4, and include tetranoic acid (C4:o), pentanoic acid (Cs:o), hexanoic acid (C6:o}, heptanoic acid (C~:o), octanoie acid (Cs:o), nonanoic acid (Cg:o)5 decanoic acid (Clo:o), wadecanoic acid (Cl:o), dodecanoie acid (Ciz:o), ~'idecanoie acid (Cls:o), tetradecanoic (myristic) acid (Ct4:o), pentadecanoic acid (Cis:o), hexadecanoic (pahnatic) acid (Cls:o), heptadecanoic acid (Cl~;o), octadecanoic (stearic) acid (Cis:o), nonadecanoic acid (Cl~:o), eicosanoic (arachidic) acid (Cao:o), heneicosanoic acid (Cm:o), docosanoic (behenic) acid (C2a:o), tricosanoic acid (C2s:o), tetracosanoic acid (Cz4;o},10-undecenoic acid (CII:z)a 11-dodecenoic acid (Cl2a), l.2-tridecenoic acid (C~3:~), myxistoleic acid (Cl4a), 10-pentadecenoic acid (Cisa), palmitoleic acid (Cilia), oleic acid (Cz$:~), linoleic acid (CiB:a), linolenic acid (Cisa), eicosenoic acid (Caoa), eicosdienoic acid (C2o:2}, eicosatrienoic acid (C2o:3), arachidonic acid (eis-5,8,11,14-eicosatetraenoic acid), and cis-5,8,11,1,17-eicosapentaenoic acid, among others. For ether analogs, the alkyl chain will also range from Cz to Cs~ pxeferably between about Ca. and about Cap.. Other fatty acid chains also can be employed as Rl andlor RZ
substituents.
Examples of such include saturated fatty acids such as ethanoic (or acetic) acid, propanoic (or propionic) acid, butanoic (or butyric} acid, hexacosanoic (or cerotic) acid, octacosanoic (or montanic) acid, triacontanoic (or melissic) acid, dotriacontanoic (or lacceroic) acid, tetratriacontanoic (or gheddic) acid, pentatriacontanoic (or ceroplastic) acid, and the like;
monoethenoic unsaturated fatty acids such as traps-2-butenoic (or crotonic) acid, cis-2-butenoic (or isocrotonoic) acid, 2-hexenoic (or isohydrosorbic) acid, 4-decanoic (or 5 obtusilic) acid, 9-decanoic (or caproleic) acid, 4-dodecenoic (or linderic) acid, 5-dodecenoic (or denticetic) acid, 9-dodecenoic (or lauroleic) acid, 4-tetradecenoic (or tsuzuic) acid, 5 tefiradecenoic (or physeteric) acid, 6-octadecenoic (or petroselenic) acid, tans-9-octadecenoic (or elaidic) acid, tans-11-octadecenoic (or vaccinic) acid, 9-eicosenoic (or gadoleic) acid, 11-eicosenoic (or gondoic) acid, 11-docosenoic (or cetoleic) acid, 13-10 decosenoic (or erucic) acid, 15-tetracosenoic (or nervonic) acid, 17-hexacosenoic (or ximenic) acid, 21-triacontenoic (or lumequeic) acid, and the like; dienoic unsaturated fatty acids such as 2,4-pentadienoic (or (3-vinylacrylic) acid, 2,4-hexadienoic~(or sorbic) acid, 2,4-decadienoic (or stillingic) acid, 2,4-dodecadienoic acid, 9,12-hexadecadienoic acid, cis-9, cis-12-octadecadienoic (or a-linoleic) acid, traps-9, tans-12-octadecadienoic (or linlolelaidic) acid, tans-l0,tans-12-octadecadienoic acid, 11,14-eicosadienoic acid, 13,I6-docosadienoic acid, 17,20-hexacosadienoic acid and the like; trienoic unsaturated fatty acids such as 6,10,14-hexadecatrienoic (or hiragonic) acid, 7,10, I 3-hexadecatrienoic acid, cis-6, cis-9- cis-12-octadecatrienoic (or y-linoleic) acid, tans-8, tans-10-tans-I2-octadecatrienoic (or (3-calendic) acid, cis-8, tans-10- cis-12-octadecatrienoic acid, cis-9, cis-12- cis-15-octadecatrienoic (or a-linolenic) acid, tans-9, tans-12- tabs-octadecatrienoic (or a-linolenelaidic) acid, cis-9, traps-11- tans-13-octadecatrienoic (or . a-eleostearic) acid, tans-9, tans-11- tans-13-octadecatrienoic (or (3-eleostearic) acid, cis-9, tans-11- cis-13-octadecatrienoic (or punicic) acid, 5,8,11-eicosatrienoic acid, 8,11,14-eicosatrienoic acid and the like; tetraenoic unsaturated fatty acids such as 4,8,11,14-hexadecatetraenoic acid, 6,9,12,15- hexadecatetraenoic acid, 4,8,12,15-octadecatetraenoic (or moroctic) acid, 6,9,12,15- octadecatetraenoic acid, 9,11,13,15-octadecatetraenoic (or a- or (3-parinaric) acid, 9,12,15,18-octadecatetraenoic acid, 4,8,12,16-eicosatetraenoic acid, 6,10,14,18-eicosatetraenoic acid, 4,7,10,13-docasatetraenoic acid, 7,10,13,16-docosatetraenoic acid, 8,12,16,19-docosatetraenoic acid and the like; penta- and hexa-enoic unsaturated fatty acids such as 4,8,12,15,18-eicosapentaenoic (or timnodonic) acid, 4,7,10,13,16-docosapentaenoic acid, 4,8,12,15,19-docosapentaenoic (or clupanodonic) acid, 7, I 0,13,16,19-docosapentaenoic, 4,7,10, 13,16,19-docosahexaenoic acid, 4,8,12,15,18,21-tetracosahexaenoic (or nisinic) acid and the like; branched-chain fatty acids such as 3-methylbutanoic (or isovaleric) acid, 8-methyldodecanoic acid, 10-methylundecanoic (or isolauric) acid, 11-methyldodecanoic (or isoundecylic) acid, 12-methyltxidecanoic (or isomyristic) acid, 13-methyltetradecanoic (or isopentadecylic) acid, 14-methylpentadecanoic (or isopalmitic) acid, 15-methylhexadecanoic, 10-methylheptadecanoic acid, 16-methylheptadecanoic (or isostearic) acid, 18-methylnonadecanoic (or isoarachidic) acid, 20-methylheneicosanoic (or isobehenic) acid, 22-methyltricosanoic (or isolignoceric) acid, 24-methylpentacosanoic (or isocerotic) acid, 26-methylheptacosanoic (or isomonatonic) acid, 2,4,6-trimethyloctacosanoic (or mycoceranic or mycoserosic) acid, 2-methyl-cis-2-butenoic(angelic)acid, 2-methyl-tans-2-butenoic (or tiglic) acid, 4-methyl-3-pentenoic (or pyroterebic) acid and the like.
[0037] The term 'hydroxyl protecting group' used herein the invention refers to the commonly used protecting groups disclosed by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
Such protecting groups include methyl ether, substituted methyl ethers including methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl ethers; substituted ethyl ethers like 1-ethoxyethyl, 1-methyl-1-benzyloxyethyl, allyl, propargyl; benzyl and substituted benzyl ethers includingp-methoxybenzyl, 3,4-dimethoxybenzyl, triphenylmethyl; silyl ethers including trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, diphenylmethylsilyl; esters including formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, benzoate, levulinylate and carbonates.
[0038] The term 'phosphate protecting group' used herein the invention refers to the commonly used protecting groups described by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
Such protecting groups include alkyl phosphates including methyl, ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl;
haloethyl phosphates including 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
[0039] The caxdiolipin molecules described herein and cardiolipins produced by the inventive method can be used in lipid formulations, such as liposomal compositions.
Complexes, emulsions and other formulations including the inventive cardiolipin also are within the scope of the present invention. Such formulations according to the present invention can be prepared by any suitable technique. The invention provides a method for preparing a liposome or other lipid composition, comprising preparing a cardiolipin or cardiolipin analogue as described herein and including the cardiolipin or cardiolipin analogue in a lipid formulation, such as a liposome. The invention also includes such lipid compositions including the inventive cardiolipin andlor cardiolipin analogues.
[0040] In addition to the inventive cardiolipin, the liposomal composition, complex, emulsion and the like can include other lipids. Thus, for example, the composition can include one or more phosphatidylcholines, such as, for example, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof. Alternatively or additionally, the composition can include one or more phosphatidylglycerols, such as dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof. Alternatively or additionally, the composition can include one or more sterols, such as cholesterol, derivatives of cholesterol, coprostanol, cholestanol, chalestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
Preferably, in addition to the cardiolipin or cardiolipin analogue, the composition includes a phosphatidylcholine, a sterol, and a tocopherol (e.g., a-tocopherol).
[0041] In addition to the cardiolipin and, optionally, other lipids, the composition also can include stabilizers, absorption enhancers, antioxidants, phospholipids, biodegradable polymers and medicinally active agents among other ingredients. In some embodiments, it is preferable for the inventive composition, especially liposomal composition, to include one or more targeting agents, such as carbohydrate or a protein or other ligand that binds to a specific substrate, for example, that recognize cellular receptors. The inclusion of such agents (such as a carbohydrate or one or more proteins selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands such as an antibody to a cellular receptor and mixtures thereof] can facilitate targeting a liposome to a predetermined tissue or cell type.
[0042] For medicinal use, the composition also can include one or more active agents.
A single active agent can be included, or a mixture of active agents (e.g., two or more active agents) can be included within the composition. Active agents (or "drugs") can be present in any suitable manner in the composition. For example, they can be complexed with the cardiolipin or cardiolipin analogue in the composition. Additionally, ox alternatively, one or more active agents can be entrapped within liposomes, when the composition is a liposomal composition.
[0043] Active agents which are compatible with the pxesent invention include, for example, agents which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synaptic sites, neuroeffector functional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, the alimentary and excretory systems, the histamine system and the central nervous system.
Suitable agents may be selected from, for example, proteins, enzymes, hormones, nucleotides (including sense and antisense oligonucleotides (see, e.g., U.S.
Patent 6,126,965), polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, .
polypeptides, steroids. Active agents can be analgesics, anesthetics, anti-arrythmic agents, antibiotics, antiallergic agents, antifungal agents, anticancer agents, anticoagulants, antidepressants, antidiabetic agents, anti-epilepsy agents, anti-inflammatory corticosteroids, agents for treating Alzheimers or Parkinson's disease, antiulcer agents, anti-protozoal agents, anxiolytics, thyroids, anti-thyroids, antivirals, anoretics, bisphosphonates, cardiac inotropic agents, cardiovascular agents, corticosteroids, diuretics, dopaminergic agents, gastrointestinal agents, hemostatics, hypercholesterol agents, antihypertensive agents (e.g., dihydropyridines), antidepressants, and cox-2 inhibitors, immunosuppressive agents anti-gout agents, anti-malarials, steroids, terpinoids, triterpines, retinouds;
anti-ulcer H2-receptor antagonists, hypoglycemic agents, moisturizers, cosmetics, anti-migraine agents, antimuscaxinic agents, antiinflammatory agents, such as agents for treating rheumatology, arthritis, psoriasis, inflammatory bowel disease, Crohn's disease; or agents for treating demyelinating diseases including multiple sclerosis, ophthalmic agents, vaccines (e.g., against pneumonia, hepatitis A, hepatitis B, hepatitis C, cholera toxin B
subunit, influenza virus, typhoid, plasmodium falciparun, diptheria, tetanus, HSV, tuberculosis, HIV,.SARS
virus, pordetela pertussis, measles, mumps and rubella vaccine (MMV), bacterial toxoids, vaccines virus, adenovirus, canary, polio virus, bacillus calmette guerin (BCG), klebsiella pneumonia, etc.), histamine receptor antagonists, hypnotics, kidney protective agents, lipid regulating agents, muscle relaxants, neuroleptics, neurotropic agents, opioid agonists and antagonists, parasympathomimetics, protease inhibitors, prostglandins, sedatives, sex hormones (e.g., estrogen, androgen), stimulants, sympathomimetics, vasodilators and xanthins and synthetic analogs of these species. The therapeutic agents can be nephrotoxic, such as cyclosporins and amphotericin B, or cardiotoxic, such as amphotericin B and paclitaxel. Exemplary anticancer agents include melphalan, chlormethine, extramustinephosphate, uramustine, ifosfamide, mannomustine, trifosfamide, streptozotocin, mitobronitol, mitoxantrone (see., e.g., published international patent application WO 02/32400), methotrexate, fluorouracil, cytarabine, tegafur, idoxide, taxanes (e.g., taxol, paclitaxel, etc., see published international patent application WO 00/01366), daunomycin, daunorubicin, bleomycin, amphotericin, carboplatin, cisplatin, paclitaxel, BCNU, vinca alkaloids (e.g., vincristine, vinorelbine (see, e.g., published international patent application WO 031018018), and the like) camptothecin and derivatives thereof (e.g., SN38 (see, e.g., published international patent application WO 021058622), irinotecan (see, e.g., published international patent application WO 03/030864), and the like), anthracyclines, antibodies, cytoxines, doxorubicin, etopside, cytokines, ribozymes, interferons, oligonucleotides and functional derivatives of the foregoing.
Additional examples of drugs which may be delivered according to the method include, prochlorperzine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzamphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperzine maleate, anisindone, diphenadione erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chloropromaide, tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-S-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17a-hydroxyprogesterone acetate, 19-norprogesterone, norgestrel, norethindrone, norethisterone, norethiederone, progesterone, norgesterone, norethynodrel, aspirin, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, diazepam, phenoxybenzamine, diltiazem, milrinone, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuinal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinolpril, enalapril, enalaprilat captopril, ramipril, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptyline, and imipramine. Further examples are proteins and peptides which.
include, but are not limited to, bone morphogenic proteins, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, digestive hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, GRF, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, LHRH agonists and antagonists, leuprolide, interferons (e.g., consensus interferon, interferon a-2a, interferon a-2b, a-, (3-, or y-interferons), interleukins, growth hormones such as human growth hormone and its derivatives such as methione-human growth hormone and des-phenylalanine human growth hormone, bovine growth hounone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors such as insulin-like growth factor, coagulation factors, pancreas hormone releasing factor, analogs and derivatives of these compounds, and pharmaceutically acceptable salts of these compounds, or their analogs or derivatives. The therapeutic agent can be a mixture of drugs or agents (e.g., two or more S agents) that can be beneficially co-administered in the liposome formulation.
[0044] Generally, liposomes can have a net neutral, negative or positive charge. For example, positive liposomes can be formed from a solution containing phosphatidylcholine, cholesterol, cardiolipin and enough stearylamine to overcome the net negative charge of cardiolipin. Negative liposomes can be formed from solutions containing phosphatidyl choline, cholesterol, andlor cardiolipin variants prepared by the methods described herein.
[0045] The liposomes of the present invention can be mufti or unilamellar vesicles depending on the particular composition and procedure to make them. Liposomes can be prepared to have substantially homogeneous sizes in a selected size range, such as about 1 micron or less, or about S00 nm or less, about 200nm or less, or about 100nm or less. One 1 S effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane.
[0046] The liposomal (or other lipid) composition can be in any desired form.
For example, for pharmaceutical use, the composition can be ready for administration to a patient. Alternatively, the composition can be in dried or lyophilized form.
Where the composition is dried or lyophilized, preferably the composition includes a cryoprotectant as well. Suitable cryoprotectants include, for example, sugars such as trehalose, maltose, lactose, sucrose, glucose, and dextran, with the most preferred sugars from a performance 2S point of view being trehalose and sucrose. Other more complicated sugars can also be used, such as, for example, aminoglycosides, including streptomycin and dihydrostreptomycin.
[0047] Any suitable method can be employed to form the liposomes. For example, lipophilic liposome-forming ingredients, such as phosphatidylcholine, a cardiolipin prepared by the methods described above, cholesterol and a-tocopherol can be dissolved or dispersed in a suitable solvent or combination of solvents and dried. Suitable solvents include any non-polar or slightly polar solvent, such as t-butanol, ethanol, methanol, chloroform, or acetone that can be evaporated without leaving a pharmaceutically unacceptable residue. Drying can be by any suitable means such as by lyophilization. The dehydration is typically achieved under vacuum and can take place either with or without 3S prior freezing of the liposome preparation. Hydrophilic ingredients can be dissolved in polar solvents, including water.
[0048] Mixing the dried lipophilic ingredients with the hydrophilic mixture can form liposomes. Mixing the polar solution with the dry lipid film can be by any means that strongly homogenizes the mixture. Vortexing, magnetic stirring and/or sonicating can effect the homogenization.
[0049] Where active agents (or a mixture of active agents) are included in the liposomes, the invention provides a method for retaining a drug in a liposome.
In accordance with the method, cardiolipin or cardiolipin analogue is prepared as described herein, and the caxdiolipin or cardiolipin analogue and a drug or drugs (e.g., an active agent a mixture of active agents) is included within a liposome. For example, active agents) can be dissolved or dispersed in a suitable solvent and added to the liposome mixture prior to mixing. Typically hydrophilic active agents will be added directly to the polar solvent and hydrophobic active' agents will be added to the nonpolar solvent used to dissolve the other ingredients but this is not required. The active agent could be dissolved in a third solvent or solvent mix and added to the mixture of polar solvent with the lipid film prior to homogenizing the mixture.
[0050] Liposomes can be coated with a biodegradable polymers such as sucrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene.
oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters.
[0051] Antioxidants can be included in the liposomal composition or other lipid composition. Suitable antioxidants include compounds such as ascorbic acid, tocopherol, and deteroxime mesylate.
[0052] Absorption enhancers can be included in the liposomal composition or other lipid composition. Suitable absorption enhancers include Na-salicylate-chenodeoxy cholate, Na deoxycholate, polyoxyethylene 9-lauryl ether, chenodeoxy cholate-deoxycholate and polyoxyethylene 9-lauryl ether, monoolein, Na tauro-24,25-dihydrofusidate, Na taurodeoxycholate, Na glycochenodeoxycholate, oleic acid, linoleic acid, linolenic acid. Polymeric absorption enhancers can also be included such as polyoxyethylene ethers, polyoxyethylene sorbitan esters, polyoxyethylene 10-lauryl ether, polyoxyethylene 16-lauryl ether, atone (1-dodecylazacycloheptane-2-one).
[0053] The inventive lipid (e.g.., liposomal) composition also can include one or more pharmaceutically acceptably excipients. For example, pharmaceutically suitable excipients include solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
The invention also includes pharmaceutical preparations in dosage units. This means that the preparations are in the form of individual parts, for example vials, syringes, capsules, pills, suppositories, or ampoules, of which the content of the liposome formulation of active agent corresponds to a fraction or a multiple of an individual dose. The dosage units can contain, for example, 1, 2, 3, or 4 individual doses, or 1/2, 1/3, or 1/4 of an individual dose.
An individual dose preferably contains the amount of active agent which is given in one administration and which usually corresponds to a whole, a half, a third, or a quarter of a daily dose.
[0054] Tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays can be suitable pharmaceutical preparations. Suppositories can contain, in addition to the liposomal active agent, suitable water-soluble or water-insoluble excipients. Suitable excipients are those in which the inventive liposomal active agent is sufficiently stable to allow for therapeutic use, for example polyethylene glycols, certain fats, and esters or mixtures of these substances.
Ointments, pastes, cream, and gels can also contain suitable excipients in which the liposomal active agent is stable. The composition also can be formulated for injection (egg., intravenously, interstitially, intratumorally, etc) by the inclusion of one or more excipients (e.g., buffered saline) suitable for injection.
[0055] The active agent or its pharmaceutical preparations can be administered intravenously, subcutaneously, locally, orally, paxenterally, intraperitoneally, and/or rectally or by direct injection into tumors or sites in need of treatment by such methods as are known or developed. Cardiolipin and cardiolipin-analog based formulations also can be administered topically, e.g., as a cream, skin ointment, dry skin softener, moisturizer, etc.
[0056] The invention provides for the use of the composition to prepare a medicament for the treatment of a disease. In this sense, the invention also provides a method for treating a human or animal disease. In accordance with the inventive method, the inventive composition is exposed to (administered to) a human or animal patient in need of such treatment. Where the composition also includes one or more active agents, the inventive method facilitates delivery of the active agents) to the patient.
[0057] The method can be used to administer one or more active agents. It is thought to be general for active agents that are stable in the presence of surfactants.
Hydrophilic active agents are suitable and can be included in the interior of the liposomes such that the liposome bilayer creates a diffusion barrier preventing it from randomly diffusing throughout the body. Hydrophobic active agents are thought to be particularly well suited for use in the present method because they not only benefit by exhibiting reduced toxicity but they tend to be well solubilized in the lipid bilayer of liposomes.
[0058] Suitable diseases for treatment will depend on the selection of active agents, such as described herein. However a preferred disease is cancer, in which instance, at least one active agent incorporated into the composition is an anticancer agent.
Chemotherapeutic agents are well suited for such use. Liposome formulations containing chemotherapeutic agents may be injected directly into the tumor tissue for delivery of the chemotherapeutic agent directly to cancer cells. In some cases, particularly after resection of a tumor, the liposome formulation can be implanted directly into the resulting cavity or may be applied to the remaining tissue as a coating. In cases in which the liposome formulation is administered after surgery, it is possible to utilize liposomes having larger diameters of about 1 micron since they do not have to pass through the vasculature.
[0059] In some embodiments, the method can be employed to treat diseases, disorders, or symptoms within patients even where the composition does not contain an active pharmaceutical agent other than cardiolipin. The invention provides for the use of cardiolipin to prepare a medicament to combat or treat such diseases, disorders, or symptoms. The invention further provides a method of treating such diseases, disorders, or symptoms within patients, and the effects of such diseases, disorders, or symptoms by administering to the patient a therapeutically effective amount of cardiolipin. Without being bound by any particular theory, it is believed that cardiolipin provides a beneficial antioxidant effect, which can alleviate the effects of many diseases, disorders, or symptoms.
Examples of conditions that can be treated in accordance with the method include, for example, age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders (e.g., acne, psoriasis, eczema, etc.). The method also can be employed to combat the effects of aging. For such use, the caxdiolipin can be formulated as a liposomal or non-liposomal formulation (e.g., an emulsion, cream, etc.) as discussed herein and can include, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
In use, the composition can be administered by any suitable route. For example, the composition can be administered dermally, intravenously, or by other desired route of administration. , [0060] The invention also is directed to methods of delivering active agents (or mixtures of active agents) to cells. The methods can be carried out by preparing liposomes that include active agents and cardiolipin variants/analogs as synthesized by the above disclosed methods. The liposomes are then delivered to a cell or cells, which can be ire vit~~o or i~ vivo, as desired. he vivo administration can be achieved as described herein or as otherwise known to those of ordinary skill. For in vitro use, delivery of the active agents) can be carried out by adding the composition (e.g., liposomes) to the cell culture medium, for example.
[0061] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
Example 1 Synthesis of Tetramyristoyl Cardioliuin lA. 2 Benzyl-1 3- bis [(1 2-dim~ristoyl-sn- lycero-3~phosphoryll~lycerol dibenzyl ester O O
R1 C-O O-C-Rl O
O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn OBn R1, R2 = myristoyl (Cl4:o chain) [0062] A solution of 1,2-dimyristoyl-sn-glycerol (10 g, 19.53 mmol), benzyl N, N
tetraisopropyl phosphoramidite (9.87 g, 29.29 mmol) and 1H-tetrazole (65 mL of 0.45 M
sol in acetonitrile, 29.29 mmol) in CH2C12 (125 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (1.18 g, 6.47 mmol) in CH2Cl2 (20 mL) was added followed by 1H- tetrazole (37.7 mL of 0.45 M sol in acetonitrile, 16.85 mmol) and stirred for 3 h. The reaction mixture was cooled to --40°C
and test-Butyl hydroperoxide (TBHP, 6.4 mL of 5-6 M sol in decane, 32.35 mmol) was added.
After stirring at --40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted mth CH2C12 (250 mL), washed f saturated aq NaZS03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 xnl,)} dried (Na2S04) and concentrated. The residue was purified on Si02 column (2:3 EtOAc: hexane) to give 6.68 g (69%) of protected cardiolipin as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.48.1H NMR
(CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J = 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
1B. 1 3 bis f(1 2 dim,~ristovl-sic- lyg~ cero-3~-phosphors]~lycerol diammonium salt (Tetramyristoyl cardiolipin) O O
R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, RZ = myristoyl (Cl4:o chain) [0063] A solution of protected cardiolipin from lA (2.5 g, 1.65 mmol) in tetrahydrofuran (40 mL) was hydrogenated at 50 psi over 10% Pd/C (900 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 4 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25~u filter and 5 precipitated with acetone to give tetramyristoyl (Cl4:o) cardiolipin (1.75 g, 83%) as a white solid. TLC (Si02) CHCl3/MeOH/NH40H (6.5:2.5:0.5) Rf~ O.SO.1H NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 80H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.06(bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1240.2 (M-2NH4++H~'), 1011.9 (M-2NH4+-10 RC00-), 619.9 (M-2NH4+)a-Example 2 _Synthesis of Tetralauroyl Cardiolinin 2A. 2 Benzyl-1 3- bis [(1 2-dilauroXl-sn- 1 cal-phosphors]glycerol dibenzyl ester O O
R~ C-O O-C-Rl O
O
O OBn O
O-P-O~O-P-O
i i OBn OBn Rl, RZ = lauroyl (Cla:o chain) [0064] Method 1: A solution of 1,2-dilauroyl-sn-glycerol (2.2 g, 4.82 mmol), benzyl N;
N tetraisopropyl phosphoramidite (1.95 g, 5.78 mmol) and 1H-tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) in CH2Cl2 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (352 mg, 1.92 mmol) in CH2C12 (10 mL) was added followed bylH- tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and Chloroperoxyperbenzoic acid (m-CPBA, 2.77 g, 9.64 mmol) was added in portions.
After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2C12 (150 mL), washed {saturated aq Na2S03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2S04) and concentrated. The residue was purified on Si02 column (2:3 EtOAc: hexane) to give 1.68 g (62%) of protected cardiolipin as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.44.1H NMR
(CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 64H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
[0065] Method 2: To a stirred solution of 1,2-Dilauroyl-s~-glycerol (5.0 g, 10.96 mmol) and tetrazole (29.2 mL of 0.45 M sol in acetonitrile, 13.15 mmol) in 40 mL
anhydrous CHZC12, dibenzyl diisopropyl phosphoramidite (4.54g, 13.15 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with100 mL of CHZC12 and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated iu vacuo and the oily residue (7.68 g) was dried in a desiccator for 8 h and used as such in the next reaction. A solution of this phosphite, 2-benzyloxy-l, 3-propanediol (0.8 g, 4.38 mmol), pyridine (4.43 mL, 54.77 mmol) and Et3N (7.63 mL, 54.77 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (5.25 g, 16.42 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (150 mL) and the organic layer~was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (NaaS04) and concentrated. The residue was purified on SiOa column (8%
acetone in CH2Cla) to give 3.8 g (62%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.44.
2B. 1 3 bis [(1 2-dilauroyl-sn-~1 cy ero-3)-phosphors]glycerol diammonium salt (Tetralauroyl cardiolipinl O O
R1 C-O O-C-Rl O
O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ O-NH4+
Ri, R2 = lauroyl (Clz:o chain) [0066] A solution of protected cardiolipin from 2A (1.5 g, 1.07 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25, filter and precipitated with acetone to give tetralauroyl (Cla:o) cardiolipin (1.0 g, 80%) as a white solid. TLC (SiOa) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.48.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 64H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 2.94 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).13C NMR 8 (CDC13, 125 MHz) 14.07, 22.67, 24.87, 24.93, 29.18, 29.22, 29.36, 29.37, 29.40, 29.57, 29.60, 29.66, 29.67, 29.69, 29.72, 31.91, 34.09, 34.28, 62.62, 63.57, 66.77, 69.47, 70.29, 173.25, 173.56. FTIR (ATR) 3207, 3035, 2956, 2918, 2850, 1737, 1467, 1378,1206,1092, 1067 cm 1. ESI-MS (negative), m/z 1150 (M-2NH4++Na~, 1127.4 (M-2NH4~, 1128.4 (M-2NH4++H~, 928.4 (M-2NH4+-RCOO-), 563.7 (M-2NH4~2-. Anal. Calculated for CS~H116N2Oi~Pz: C, 58.84; H, 10.05; N, 2.41:
P, 5.32.
Found: C, 57.75; H, 9.83; N, 2.34: P, 5.28.
Example 3 Synthesis of Tetralaurovl Cardioliuin [0067] In this method the tetralauroyl cardiolipin was synthesized by 2-cyanoethyl phosphoramidite.
3A. 2 Benwl 1 3 bis f(1 2-dilaurovl-sh-glycero-3~-phosphoryl]~lycerol dicyanoethyl ester O O
R~ C-O O-C-Rl O O
O OBn O
O-P-O~O-P-O
i i /O O\
NC Jr l'CN
Rl, R2 = lauroyl (Cla:o chain) [0068] To a mixture of 1,2-dilauroyl-sn-glycerol (1.74 g, 3.79 mmol) and N, N
diisopropylethylamine (545 mg, 4.22 mmol) in anhydrous ether (20 mL) under argon atmosphere was added 2-cyanoethyl diisopropylchlorophosphoramidite (1 g, 4.22mmo1).
The mixture was stirred at room temperature for lh, the separated disiopropylamine hydrochloride was filtered, and the filtrate was concentrated iu vacuo. The residue was as such used for the phosphorylation.
[0069] To a mixture of above phosphoramidite and 1H-tetrazole (9.4 mL of 0.45 M sol in acetonotrile, 4.22 mmol) in anhydrous CHaCl2 (30 mL) was added a solution of 2-benzyloxy 1,3-propanediol (312 mg, 1.71 mmol) in CH2C12 (5 mL). The reaction mixture was stirred at room temperature for 3 h and cooled to -40°C and m-CPBA
(1.36 g, 4.73 mmol was added in portions. After stirring at --40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2C12 (200 mL), washed f saturated aq NaaS03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2S04) and concentrated. The residue was purified on SiOz column (1:4 acetone:
CHaCl2) to give 1.48 g (70%) as colorless syrup. TLC (SiOa) EtOAc/ CH2C12 (1:3) Rf~ 0.48.1H
(CDCl3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.66 (m, 8H), 2.26-2.36 (m, 8H), 2.64-2.75 (m, 4H), 3.83-3.88 (m, 1H), 4.06-4.36 (m, 16H), 4.67 (s, 2H), 5.19-5.28 (m, 2H), 7.28-7.38 (m, SH).
3B. 1,3- bis 1f 1,2-dilauroyl-sn-~1 c~ero- 1-phosphorxll-, 2-~~l~.l~cerol diammonium salt O o R~ C-O O-C-Rl O
O
R2 C O O-C-Ra O OBn O
O-P-O~O-P-O
ONHq+ O'NH4+
Rl, R2 = lauroyl (Cla:o chain) A solution of the precursor from 3A (1.48 g, 1.2 mmol) and Et3N (1.66 mL, 12 mmol) in 10 mL acetonitrile was stirred overnight (TLC showed no remaining starting material) and evaporated to dryness. The residue was converted into ammonium salt by adding 2 mL of NHøOH and purified on SiO2 column (15% MeOH in CH2C12 containing 1% NH40H) to give 850 mg (60%) as colorless syrup that slowly solidified.iH NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.63 (m, 8H), 2.22-2.34 (m, 8H), 3.66-3.76 (m, 1H), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14-5.26 (m, 2H), 7.22-7.36 (m, SH), 7.49 (bs, 8H).
3C. 1 3 bis [(1 2-dilauroyl-sn-~lycero-3~phosphor~]glycerol diammonium salt (Tetralauroyl cardiolipinl O o R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = lauroyl (CIZ:o chain) [0070] A solution of protected cardiolipin from 3B (1.12 g, 0.89 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (450 mg) for 10 h. The catalyst was filtered off over celite bed and concentrated, the residue was dissolved in CHC13, filtered through a 0.25 ~, filter and precipitated with acetone to give tetralauroyl (Cia:o) cardiolipin (750 mg, 75%) cardiolipin as a white solid. TLC (Si02) column CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.48. The tetralauroyl cardiolipin prepared by this method described herein is identical to that of 2B in all aspects.
Example 4 Synthesis of Tetradecanovl Cardiolinin 4A. Synthesis of 1 2-Didecanoyl-3-benzyl-sh-~lycerol O
O-C-Rl O
ii O_C_R2 Bn0 R1, R2 = decanoyl (Clo:o chin) [0071] To an ice cooled solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (2.0 g, 10.97 mmol) and Et3N (6.89 mL, 49.36 mmol) in CH2Cl2 (30 mL) was added decanoyl chloride (5.1 mL, 24.69 mmol) dropwise over a period of 10 minutes followed by 4-(Dimethylamino)pyridine (DMAP, 268 mg, 2.19 mmol). The reaction mixture was stirred at room temperature for 12 h, diluted with CH2C12 (200 mL) washed successively with water (100 mL) and brine (100 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 cohunn (3% EtOAc in hexane) to give 4.5 g (83%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (9:1) Rf ~ 0.54. 1H NMR ~ (CDC13, 300 MHz) 0.87 (t, J
= 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J = 4.2 Hz, 2H), 4.18 (dd, J = 6.4 and 11.9 Hz, 1H), 4.34 (dd, J = 6.4 and 11.9 Hz, 1H), 4.51 (d, J =
12.2 Hz, 1H), 4.57 (d, J =12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
4B. 1 2-Didecanoyl-s~-gl cy erol O
O-C-Rl O
ii HO
R1, Ra = decanoyl (Clo:o chain) [0072] A solution of protected didecanoylglycerol from 4A (4.68 g, 9.55 mmol) in EtOH: EtOAc: AcOH (9:1:0.1) (40 mL) was hydrogenated at 40 psi over 10% PdIC
(600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DDG (3.52g, 92%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.39.1H NMR ~ (CDCl3, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, Da0 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2. 3 5 (t, J = 7. 6 Hz, 2H) 3 .73 (t, J = 6.0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4.3 3 5 (dd, J= 5.8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
4C. 2-Benzyl 1 3 bis f(1 2-didecanoyl-sn-~lvcero-31-nhos~horyll~l_Ycerol dibenzyl ester O O
R~ C-O O-C-Rl O
ii R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn ~ OBn R1, R2 = decanoyl (Cio:o chain) [0073] A solution of 1,2-didecanoyl-sh-glycerol from 4B (3.52 g, 8.8 mmol), benzyl N, 10 N tetraisopropyl phosphoramidite (3.26 g, 9.68 mmol) and 1H-tetrazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) in CH2C12 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (712 mg, 3.9 mmol) in CH2C12 , (10 mL) was added followed by 1H- tetrazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and m-CPBA (5.06 g, 15 17.6 mmol) was added in portions. After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CHaCl2 (200 mL), washed f saturated aq Na2S03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 xnL)}
dried (Na2S04) and concentrated. The residue was purified on SiOa column (2:3 EtOAc:
hexane) to give 3.21 g (64%) of protected cardiolipin as colorless syrup. TLC
(Si02) 20 hexane/EtOAc (3:2) Rf~ 0.44.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 48H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
4D. 1 3- bis [~1 2-didecano~l-s~- lycero-3~-phos~horyll~lvcerol diammonium salt O O
Rl-C-O O-C-Rl O
Ra C-O O-C-R2 O OH O
O-p-O~O-P-O
O'NH4+ ~O-NH~+
Rl, RZ = decanoyl (Clo:o chain) [0074] A solution of protected cardiolipin from 4C (1.5 g, 1.16 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25~u filter and concentrated to give tetradecanoyl (Clo:o) cardiolipin (1.0 g, 80%) as a semi solid. TLC
(SiO2) CHC13/MeOH/NHaOH (6.5:2.5:0.5) Rf~ 0.42.1H NMR ~ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 48H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.62 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1038 (M-2NH4++Na+), 1015 (M-2NH4+), 843.7 (M-2NH4+-RCOO-), 507.5 (M-2NH4+)a-.
Example 5 Synthesis of Tetraoctanovl Cardiolinin 5A. 1,2-Dioctano~-3-be., l-sn-glXcerol O
O-C-Rl O
~i Bn0 R1, R2 = octanoyl (CB:o chain) [0075] To a solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (4.Og, 21.95 mmol) in anhydrous pyridine (40 mL) was added octanoyl chloride (8.93 g, 54.87 mmol) dropwise over a period of 10 minutes followed by DMAP (267 mg, 2.19 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (300 mL) washed successively with water (100 mL), 1N HCl (2 x 100 mL) and brine (100 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (3% EtOAc in hexane) to give 7.3 g (75%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (9:1) Rf~ 0.52.1H NMR 8 (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.4 and 11.9 Hz, 1H), 4.34 (dd, J=
6.4 and 11.9 Hz, 1H), 4.51 (d, J= 12.2 Hz, 1H), 4.57 (d, J= 12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
SB. 1 2-Dioctanoyl-sn-glycerol O
O-C-Rl O
ii O-C-RZ
HO
R1, R2 = octanoyl (CB:o chain) [0076] A solution of protected dioctanoyl glycerol from SA (6.8 g, 15.66mmo1) in EtOH: EtOAc: AcOH (9:1:0.1) (30 mL) was hydrogenated at 40 psi over 10% PdIC
(900 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DOG (5.0, 93%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.31.1H NMR ~ (CDCl3, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, D20 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J
= 7.6 Hz, 2H) 3 .73 (t, J = 6. 0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4. 3 3 (dd, J = 5 . 8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
SC. 2-Benzyl-1 3- bis j(1 2-dioctanoXl-sn- 1 cy ero-3~phosphoryll~lycerol dibenzylester O O
R~ C-O ~ O-C-Rl O O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i OBn OBn R1, RZ = octanoyl (Cs:o chain) [0077] To a solution of 1,2-Dioctanoyl-sn-glycerol from SB (5.0 g, 14.53 mmol) and tetrazole (40.3 mI, of 0.45 M sol in acetonitrile, 18.16 mmol) in 50 mL
anhydrous CHaCl2, dibenzyl diisopropyl phosphoramidite (6.26g, 18.16 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of EtOAc and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ih vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0078] A solution of above phosphate, 2-benzyloxy-1, 3-propanediol (0.660 g, 3.63 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CHaCl2 (40 mL) was cooled to --40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL).
The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (10% acetone in CHZCIz) to give 2.72 g (64%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (3:2) Rf ~ 0.44.
1H NMR 8 (CDCl3, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 32H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, IH), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (rn, 4H), 5.15-5.18 (m, 2H), 7.28-IS 7.36 (m, 15H).
5D. 1,3- bas f(1,2-dioctanoyl-sv~-~lycero-31-bhosnhoryll-2-benzvl ~lvcerol diammonium salt _n_ Ra C O O-C-RZ
O OBn O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = octanoyl (CB;o chain) [0079] A solution of protected cardiolipin from SC (2.5 g, 2.12 mmol) in 2-butanone (15 mL) and sodium iodide (956 mg, 6.36 mmol) was refluxed at 90°C fox 3 h. The volatiles were evaporated and the residue was purified on SiOa column (20% methanol in CH2Cl2 containing 1 % of ammonia) to give 1.52 g (75%) of the product as colorless semisolid. TLC
(SiOz) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.53.1H NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.66-3.76 (m, 1H), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14-5.26 (m, 2H), 7.22-7.36 (m, 5H), 7.49 (bs, 8H).
SE: 13- bis f(1,2-dioctanovl-sn-gl_ycero-3~phosphoryl]glycerol diammonium salt o O
Ri C-O O-C-Rl O
ii R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = octanoyl (CB;o chain) [0080] A solution of protected cardiolipin from SD (1.5 g, 1.27 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25, filter and concentrated to give C~ cardiolipin (950 mg, 80%) as a semi solid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.43.1Ii NMR 8 (CDCl3, 500 MHz) 0.88 (t~
.I=
7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).
ESI-MS
(negative), m/z 925.7 (M-2NH4++Na++)-, 903.1(M-2NH4~, 760.6 (M-2NH4+-RCOO-), 451.2 (M-2NH4+)2-.
Example 6 Synthesis of Tetrahexanoyl Cardiolinin 6A. 1 2-Dihexanoyl-3-benzyl-sv~- lycerol O
O_C_Rl O
ii Bn0 Rl, RZ = hexanoyl (C6;o chain) [0081] To a solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (2.6 g, 14.26 mmol) in anhydrous pyridine (30 mL) was added hexanoyl chloride (4.8 g, 35.67 mmol) dropwise over a period of 10 minutes followed by DMAP (175 mg, 1.42 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (200 mL) washed successively with water (100 mL), 1N HCl (2 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated. The residue was purified on SiOa column (3% EtOAc in hexane) to give 4.1 g (76%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (9:1) Rf~ 0.48.1H NMR S
(CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.4 and 11.9 Hz, 1H), 4.34 (dd, J=
6.4 and 11.9 Hz, 1H), 4.51 (d, J=12.2 Hz, 1H), 4.57 (d, J=12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
6B. 1 2-Dihexano~-sn-gl c O
O-C-R~
O
ii O-C-RZ
HO
R1, R2 = hexanoyl (C6:o chain) , [0082] A solution of protected dihexanoylglycerol from 6A (3.1 g, 8.2 mmol) in EtOH:
EtOAc: AcOH (9:1:0.1) (30 mL) was hydrogenated at 40 psi over 10% Pd/C (600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated;
the resulting glycerol (3.52g, 92%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf 0.34.1H NMR ~ (CDC13, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, D20 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J=
7.6 Hz, 2H) 3 .73 (t, J = 6.0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4.3 3 (dd, J = 5 . 8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
6C: 2 Benz~l 1 3 bis [(1 2 dihexanoyl-sn-glycero-31-phosphoryll ~lycerol dibenzyl ester R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn OBn R1, R2 = hexanoyl (C6:o chain) [0083] To a solution of 1,2-Dihexanoyl-sn-glycerol from 6B (3.Sg, 13.19 mmol) and tetrazole (35.1 mL of 0.45 M sol in acetonitrile, 15.83 mmol) in 40 mL
anhydrous CH2C12, dibenzyl diisopropyl phosphoramidite (5.46g, 15.83 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of CHZCl2 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ire vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0084] A solution of above phosphite, 2-benzyloxy-1, 3-propanediol (0.957 g, 5.25 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL).
The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (10% acetone in CH2C12) to give 3.57 g (64%) of the product as colorless syrup. TLC (SiO~) hexane/EtOAc (3:2) Rf ~ 0.40.
1H NMR 8 (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
6D: 1.3- bis f(1,2-dihexanoyl-sn-~lycero-3~phosphoryll ~lycerol diammonium salt R~ C-O O-C-R~
O
R2_C_O O_C_Ra O OH O
O-P-O~O-P-O
ONH4+ ~-~4+
Rl, Rz = hexanoyl (C6:o chain) [0085] A solution of protected cardiolipin from 6C (1.5 g, 1.41 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHCl3, filtered through a 0.25, filter and concentrated to give C6 cardiolipin (940 mg, 81 %) as a semi solid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.36.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J=
7.0 Hz, 12H), 1.22-1.34 (m, 16H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).
ESI-MS
(negative), mlz 813 (M-2NH4++Na~), 791 (M-2NH4++H+), 395 (M-2NH4+)z-.
Example 7 Synthesis of Tetraoleovl Cardiolipin (unsaturated) 7A. Cis 5 Levulinoyl-2-phenyl-1 3-dioxane O
O
O
O O
[0086] To a solution of cis-1,3-O-benzylideneglycerol (5.0 g, 27.74 mmol) in (80 mL) at 0°C, DCC (8.58 g, 41.61 mmol), DMAP (3,38 g, 27.74) and levulinic acid (4.0 g, 34.68 mmol) were sequentially added. The mixture was stirred for 24 hrs at room temperature. The separated urea was filtered, the filtrate was concentrated and purified by.
flash chromatography with 80% EtOAc/hexane as eluent to afford the product as a white solid (5.86 g, 76%). TLC (SiOa) hexane/EtOAc (l:l) Rf~ O.S1.1H NMR 8 (CDC13, MHz) 2.19 (s, 3H), 2.58-2.89 (m, 4H), 4.18 (dd, J= 12.0, 1.5 Hz, 2H), 4.25 (dd, J=12.0, 1.5 Hz, 2H), 4.71 (dd, J= 1.5, 1.5 Hz, 1H), 5.55 (s, 1H), 7.24-7.53 (m, SH).
7B. 2-Levulinoyl-1 3-propanediol O
O
O
HO~OH
[0087] A solution of protected glycerol 7A (5.8 g, 20.86 mmol) in EtOH: EtOAc (1:1) (100 mL) was hydrogenated at 50 psi over 10% PdIC (800 mg, 10%) for 8 h. The catalyst was filtered off over celite bed and concentrated; the resulting 2-levulinoyl glycerol was purified by flash chromatography with 6% MeOH/CHaCl2 as eluent to afford the product as a white solid (2.82 g, 70%). TLC (Si02) MeOH/CH2Cla (1:9) Rf ~ 0.31.1H NMR 8 (CDCl3, 300 MHz) 2.19 (s, 3H), 2.58 (dd, J= 6.0, 6.0 Hz, 2H), 2.80 (dd, J= 6.0, 6.0 Hz, 2H), 3.09.
(bs, 2H), 3.72-3.87 (m, 4H), 4.90 (q, J= 5.1 Hz).
7C. 2 Levulinoyl 1 3 bis f(1 2-dioleoyl-sh-gl cy ero-31-phosphoryll~lycerol dibenzyl ester O
R~ C-O O-C-Ri O O
R2_C_O O_C_R2 O OLev O
O-P-O~O-P-O
i i OBn OBn Ri, R2 = oleoyl (CiB;i chain) O
Lev =
O
[0088] To a solution of 1,2-Dioleoyl-sn-glycerol (l.Sg, 2.41 mmol) and tetrazole (8 mL
of 0.45 M sol in acetonitrile, 3.62 mmol) in 20 mL anhydrous CHZCIa, dibenzyl diisopropyl phosphoramidite (1.25g, 3.62 mmol) was added and stirred at room temperature for 2 h.
The contents were diluted with100 mL of CH2C12 and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ih vacuo and the oily residue (2.08 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0089] A solution of above phosphite, 2-levulinoyl-1, 3-propanediol from 7B
(0.185 g, 0.96 mmol), pyridine (2 mL, 24.1 mmol) and Et3N (1.2 mL, 12.05 mmol) in CH2Cla (20 mL) was cooled to -40°C and pyridinium tribromide (1.15 g, 3.61 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (10 mL). The contents were diluted with EtOAc (100 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (5% acetone in CH2Cl2) to give 1.09 g (66%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (1:2) Rf ~ 0.64.
iH NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 1.96-2.07 (m, 16H), 2.15 (s, 3H), 2.22-2.31 (m, 8H), 2.52-2.57 (m, 2H), 2.66-2.74 (m, 2H), 4.01-4.32 (m, 12H), 5.01-5.10 (m, SH), 5.15-5.18 (m, 2H), 5.28-5.39 (m, 8H), 7.28-7.39 (m, lOH).
7D. 1,3 bis f(1 2 dioleoyl sh slycero-31-phosnhoryll-2-levulinoyl ~lycerol diammonium salt R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OLev O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, RZ = oleoyl (ClBa chain) [0090] A solution of protected cardiolipin from 7C (0.525 g, 0.324 mmol) in 2-butanone (8 mL) and sodium iodide (145 mg, 0.972 mmol) was refluxed at 90°C for 3 h.
The volatiles were evaporated and the residue was purified on SiOa column (10%
methanol in CHZCIa containing 1 % of ammonia) to give 240 mg (50%) of the product as colorless semisolid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.63.1H NMR ~ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.96-2.07 (m, 16H), 2.18 (s, 3H), 2.23-2.35 (m, 8H), 2.52-2.59 (m, 2H), 2.71-2.79 (m, 2H), 3.83-4.04 (m, 6H), 4.12-4.23 (m, 4H), 4.31-4.39 (m, 2H), 5.01-5.09 (m, 1H), 5.17-5.26(m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1576.5 (M-2NH4++Na~', 1554 (M-2NH4~, 1272.2 (M-2NH4+-RCOO-), 776 (M-2NH4+)a .
7E. 1 3 bis j(1 2 dioleoyl sh ~lycero-3)-phosphor~l]glycerol diammonium salt (Synthesis of Tetraoleoyl Cardiolipin O O
Rl_C_O O_C_Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
ONH4+ O~ -NHq.+
Rl, R2 = oleoyl (C18;1 chain) [0091] To a solution of lev- protected cardiolipin from 7D (140 mg, 0.088 mmol) in pyridine:acetic acid (3 mL, 4:1) was added hydazine (14 mg, 0.44 mmol) and stirred for 30 minutes. The volatiles were removed in rotavapor and the residue was purified on Si02 (10% methanol in CH2Cla containing 1% of ammonia) to give 80 mg (61%) of the product as colorless semisolid. TLC (Si02) (6.5:2.5:0.5) Rf~ O.SS.1H NMR 8 (CDCl3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.82 (bs, 1H), 1.96-2.07 (m, 16H), 2.23-2.35 (m, 8H), 3.83-3.94 (m, 7H), 4.12-4.23 (m, 4H), 4.33-4.39 (m, 2H), 5.17-5.23 (m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1478 (M-2NH4++Na )', 1456 (M-2NH4+), 1174.2 (M-2NH4+-RCOO'), 727.5 (M-2NHa~2'.
5 Cardiolinin Ether Analogs Example 8 Synthesis of Tetralauryl cardiolinin 8A. 2-Benz~l-1 3- bas [(1 2-dilaui I-;y sn-,~I" ce~ro-3_~ hn OSbhor~l~lycerol dibenzyl ester R10 ORl O OBn O
O-P-O~O-P-O
i i OBn OBn IO
R1, R2 = lauryl (Cla:o chain) (0092] To a stirred solution of 1,2-Dilauryl-s~-glycerol (3.0 g, 7.00 mmol) and tetrazole (19.5 mL of 0.45 M sol in acetonitrile, 8.76 mmol) in 40 mL anhydrous CH2C12, dibenzyl 1~5 diisopropyl phosphoramidite (3.02g, 8.76 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with100 mL of CH2Cla and then washed with 5%
aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated in vacuo and the oily residue (4.5 g) was dried in a desiccator for 8 h and used as such in the next step reaction.
20 [0093] A solution of above phosphate, 2-benzyloxy-1, 3-propanediol (0.48 g, 2.67 mmol), pyridine (5.43 mL, 66.8 mmol) and Et3N (4.63 mL, 33.4 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (3.25 g, 10.02 mmol) was added at a time.
The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were 25 diluted with EtOAc (150 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on SiOa column (30% ethylacetate in hexane) to give 2.34 g (67%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf 0.47. IH NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 6.6 Hz, 12H), 1.22-1.34 (m, 72H), 1.47-30 1.56 (m, 8H), 3.35-3.58 (m, 14H), 3.72-3.78 (m, 1H), 3.95-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.07 (rn, 4H), 7.26-7.34 (m, 15H).
8B: 1 3 bis [(1 2 dilaur ly sh glycero-3~~hosphor~]glycerol diammonium salt (Tetralauryl Cardioliuinl O OH O
O-P-O~O-P-O
O'NH4+ O-NH4+
Rl, R2 = lauryl (Cla:o chain) [0094] A solution of protected cardiolipin from 8A (650 mg, 0.48 mmol) in tetrahydrofuran (20 mL) was hydrogenated at 50 psi over 10% PdIC (200 mg) for 6 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25, filter and precipitated with acetone to give Ci2 cardiolipin (400 mg, 75%) as a white semisolid. TLC
(Si02) CHCl3/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.39.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 72H), 1.52-1.66 (m, 8H), 3.39-3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.59 (bs, 8H). ESI-MS (negative), m/z 1094.1 (M-2NH4++Na ), 1072.0 (M-2NH4++H+), 535.5 (M-2NH4~2-.
Example 9 Synthesis of Tetrahexyl Cardiolipin 9A. 2 Benzyl 1 3 bis j(1 2-dihexvl-s~~lycero-3)-phosphorvll~lvcerol dibenzyl ester Ra0 ORa O OBn O
O-P-O~O-P-O
OBn OBn R1, R2 = hexyl (C6;o chain) [0095] The title compound was prepared according to the method described in example 8A. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.39.1H NMR 8 (CDCl3, 300 MHz) 0.88 (t, J=
6.6 Hz, 12H), 1.22-1.37 (m, 24H), 1.47-1.58 (m, 8H), 3.34-3.58 (m, 14H), 3.72-3.78 (m, 1H), 3.94-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.08 (m, 4H), 7.26-7.34 (m, 15H).
9B: 1 3 bis ((1 2 dihex~l_ sh ~lycero 31-phosphorXll~lyc~ opium salt (Tetrahexvl Cardiolipinl R10 ORl O OH O
O-P-O~O-P-O
O-NHq+ ~-NH4+
Rl, R2 = hexyl (C6;o chain) [0096] The title compound was prepared according to the method described in example 8B.TLC (SiOa) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.31.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 24H), 1.50-1.61 (m, 8H), 1.88 (bs, 1H), 3.39-3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.69 (bs, 8H).
Example 10 [0097] This example demonstrates preparation of a cardiolipin-containing liposome composition of the invention. Small unilamellar vesicles are formed by mixing 19.1 ~umole of cardiolipin, produced according to the methods described herein, 96.2 ~,mol of phosphatidyl choline and 64.6 ~,mol of cholesterol. After thorough stirring, the mixture is evaporated to dryness in a 50 ml round-bottom flask using a rotary evaporator.
The subsequent dried lipid film is resuspended in 10 ml sterile non-pyrogenic water. After a 30 minute swelling time, the resulting suspension is sonicated in a fixed temperature bath at 25 °C for 15 minutes. The preparation of liposomes is then lyophilized with trehalose.
[0098] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
(0099] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having,"
"including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00100] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments might become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subj ect matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
References 1. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadgopoulos, D.
Pharm. Rev. ,1999, 51, 691-743 .
2. Ramirez, F.; Ioannou, P. V.; Marecek, J. F.; Golding, B. T.; Dodd, G. H.
Synthesis.
1976,11, 769-770.
3. Duralski, A. A.; Spooner, P. J. R.; Watts, A. Tetrahedron Lett. 1989, 30, 3585-3588.
4. Duralski, A. A.; Spooner, P. J. R.; Rankin, S. E.; Watts, A. Tetrahedron Lett.1998, 39, 1607-1610.
5. Saunders, R. M.; Schwaxz. J. Am. Chem. Soc. 1966, 88, 3844-3847.
6. Mishina, I. M.; Vasilenko, A. E.; Stepanov, A.E.; Shvets, V. I. Bioorg.
Khinz. 1985, 11, 992-994.
7. Stepanov, A.E.; Makarova, I. M.; Shvets, V. I. Zh. Org., Khim. 1984, 20, 985-988.
8. DeHaas, G.H.; Bonsen, P.P.M.; VanDeenen, L.L.M. Biochim. Biophys.
Acta,1966, 116: 114-124.
9. moue, K.; Suhara, Y.; Nojima, S. Chem. Pharm. Bull.,1963, 1150-1156.
10. Browne, J. E.; Driver, M. J.; Russet, J. C.; Sammes, P. G. J. Chem. Soc.
Pe~ki~
Tr~ans. 1. 2000, 653-657.
11. Watanabe, Y.; Inada, E.; Jinno, M.; Ozaki, S. Tetr~ahedro~c Lett. 1993, 34, 497-500.
Y_ ,~x Y Y
~--'N P ~N...P_N~
Cl OX
IV v [0023] In another embodiment, the invention provides a method for preparing cardiolipin or an analogue thereaf of formulas I, II, or III; comprising reacting 2-O
protected glycerol with one or more phosphotriesters in the presence of pyridinium tribromide. Preferred phosphotr~iesters can be produced by reacting an alcohol of formula VIII with phosphoramidite of general formula VII.
~--N--P-OX
OX
VII
[0024] X in Formutas IV, V, ox VII is a phosphate protecting group, preferably a benzyl group or 2-cyanoethyl or silyl group. Other examples of suitable protecting groups include allcyl phosphates including ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2-trichloroethyi, 2,2,2-tribrornoethyl, 2,2,2-trifluoxoethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
[0025] A general sequence of reactions for the synthesis of compound of invention is illustrated in Figures 2 & 3.The present invention provides a method for preparing cardiolipin I having varying fatty acid chain lengths comprising (a) reacting an optically pure 1,2-O-diacyl s~-glycerol 2 with one or more phosphorarx~idite reagent(s)of the general formula IV (figure 2) or V (figure 3) (b) coupling the product of (a) 3 with a 2-O-protected glycerol VI in a chlorinated solvent (for example dichloramethane, chloroform or like) followed by oxidation with m-chloroperoxybenzoic acid (m-CPBA) results in the production of a protected cardiolipin 4. Thereafter, deprotecting the protected cardiolipin followed by conversion to ammonium salt will result in the production of cardiolipin 1 (ammonium salt).
[0026] For reaction with optically pure 1,2-O-diacyl sre-glycerol 2, any suitable phasphoramidite reagent or methodology may be used, such as is described in, for example Browne et al., supra. Bxasnples of suitable phosphoramidite reagents include (benzyloxy)(N, N diisopropylamino)chlorophosphine (see, e.g., Prestwich et al.
J. .Ntrn.
Chem. hoc. 1.991,113, 1822-1.825), benzyloxybis (diisopropylamino) phosphine (see, e.g., Dreef et al. Tetr~ahednon Lett. 1988, 29, 6513-6516), 2-cyanoethyl-N, N, N, .N
tetraisopropylphosphoramidite (see, e.g., Browne et al. J. Chem. Soc. Per~kir~
Tans. 1. 2000, 653-657.), (2-cyanoethyl)(N,~V diisopropylaznino)chlorophosphine (see, e.g., Prestwich et al. J. O~g. Chem. 1998, 63, 6511-6522), difluorenyl diisopropylphosphoramidite (see, e.g., Watanabe et al. Tet~ahed~on Lett. 1997, 3S, 7407-7410), methyl-N, N, N, N
tetraisopropylphosphorodiamidite (see, e.g., Murakami et al. J. Or~g. Chern.
1999, 64, 648-651), dimethyl N, N-diisopropylphosphoraznidite (see, e.g., Watanabe et al.
Tetr~ahedr~on Lett. 1993, 34, 497-500), dibenzyl diisopropylphosphoramidite (see, e.g., Watanabe et al.
Tet~ahedr~on Lett. 2000, 41, 8509-8512), di-te~t"butyl-N,N
diisopropylphosphoramidite (see, e.g., Lindberg et aI. J. Or~g. Chew. 2002, 67, I94-199.), 2-(diphenylmethylsilyl)ethyl-N, N, N, N tetraisopropylphosphoramidite (see, e.g., Chevallier et al. Or g Lett. 2000, 2, 1859-x861), (N-trifluoroacetylamino) butyl and (N-trifluoroacetylamino) pentyl N N, N, N
tetraisopropylphosphoramidites (see, e.g., wilk et al. J. O>"g. Chem. 1.997, 62, 6712-6713).
[0027] Another embodiment of the present invention is depicted in Figure 4. Tn this method the optically pure 1,2-O-diacyl-sn-glycerol 2 can be phosphorylated using phosphoranv.dite VII to yield phosphate triesters 5 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol ar levulinoyl-1, 3-propanediol using pyxidizuuzn perbrolnide and phosphoniuzn salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin 4. The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopxopylphosphoramidite.
(0028] In an alternative strategy set fozfih in Figure 5, the inventive method comprises (a) reacting a 2-O-protected glycerol VI with one or more phosphoramidite reagents IV or V, wherein a phosphorylating agent 6 is produced, (b) reacting the phosphorylating agent b with an optically pure 1,2-O-diacyl-srx-glycerol 2 followed by oxidation with m-CPBA, wherein a protected cardiolipin 4 is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. Suitable phosphoramidite reagents and 2-O-protected glycerols fvr use in this aspect of the izzventive method are described above.
(0029] Another embodiment of the present invention, represented in Figure 6 leads to ether azlalogs of cardioiipin, wherein the acyl groups are replaced by all~.yl chain.
Accordingly (a) 1,2-O-dialkyl-sn-glycerol 7 is treated with phosphoraznidites IV ox V
wherein a pl~osphozylating agent 8 is produced, (b) reacting the phosphorylating agent with a 2-O-protected glycerol VI followed by oxidation, wherein a protected cardiolipin 9 is produced, and (c) deprotecting the protected cardiolipin, such that the ether analog of cardiolipin 10 is produced.
[0030] Another embodiment ofthe present invention is depicted in Figure 7. In this method the optically pure I,2-O-dialkyl-stz-glycerol 7 can be phosphorylated using phosphoramidite VII to yield phosphate triestexs 11 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy I,3-propanediol or levulinoyl-I, 3-propanediol using pyridinium perbromide and phosphonium salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin ether analog 9.
The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
[0031] The invention described above is an elegant and efficient method of synthesizing cardaolipin. The routes are short and proceed in good overall yield. The deprotectaon can be accomplished by a method depending on the protecting group. For example a benzyl group can be removed by catalytic hydrogenolysis or by treatment with NaT, 2-cyanoethyl and fluorenylmethyl groups by treatment with a tertiary base such as triethylamine, a silyl group can be deprotected with fluoride ion or acidic medium, a levulinoyl group by hydrazinolysis.
[0032] The synthetic methods described herein can be modified in any suitable manner.
Fox example, phosphoramidites and phosphate esters can be prepared using a variety of acid catalysts, including 4,5-dichloroimidazole (see, e.g., Browne et al.), 5-(4-nitrophenyl)-1H
tetrazole, 5-(3,5-dinitrophenyl)-IH tetrazole, N-methylimi.dazolium traflate, and N-methylimidazolium perchlorate (see, e.g., Moriguchi et al.). Likewise, tert-butylhydroperoxide can be used as an alternative oxidant. The described methods can be further modified in any suitable manner known in the art.
[0033] The inventive method can be used to prepare cardaolipin species comprising fatty acid lalkyl chains of varying length and saturation/unsaturation. The general structure of a phospholipid fatty acid comprises a hydrocarbon chain and a carboxylic acid group. In general, the length of the fatty acid hydrocarbon chain ranges from about 2 to about 34 carbon atoms and can be saturated or unsaturated. I~owever, the carbon chain is more typically between about I2 and about 24 carbon atoms. In some embodiments, it is desirable for the hydrocarbon chain to comprise, for example, at least about 5 carbon atoms or at least about 10 carbon atoms ox even at least about 15 carbon atoms.
Typically, the length of the fatty acid hydrocarbon is less than about 24 carbon acids, such as less than.
about 24 carbon atoms, or even less than about 20 carbon atoms.
[003] The invention also provides a cardiolipin or cardaoliphl analogue prepared in accordance with the inventive method. Most preferably, the cardaolipin prepared by the inventive method comprises a short fatty acid chain (i.e., a "short chain cardiolipin"), and the invention provides a short chain cardiolipua. A short fatty acid chain comprises between about 2 and between about I4 carbon atoms, and can have between about 4 (or about 6) and about 12 carbon atoms, such as between about 8 and about 10 carbon atoms.
Alternatively, the cardiolipin produced by the inventive method can comprise a long chain fatty acid chain (i.e., a "long chain cardiolipin"). A long fatty acid chain comprises between about 14 and about 34 carbon atoms, such as between about 14 (or between about 20) and about 24 carbon atoms. The inventive method is not limited to the production of shoat or long chain cardiolipin species exclusively. Indeed, a eaxdialipin containing fatty acid/alkyl chains of intermediate length can also be prepared by the inventive method.
[U035] Phospholipid fatty acids typically are classified by the number of double and/or triple bonds in the hydrocarbon chain (i.e., unsaturation}. A saturated fatty acid does not contain any double or triple bonds, and each carbon in the chain is bound to the maximum number of hydrogen atoms. The degree of unsaturation of a fatty acid depends on the number of double or triple bonds present in tl~.e hydrocarbon chain. 1n this respect, a monounsaturated fatty acid contains one double bond, whereas a polyunsaturated fatty acid contains two or more double bonds (see, e.g., Oxford Dictionary ofBiochemistry and Moleculas~ Biology, rev. ed., A.D. Smith (ed.), Oxford University Press (2000), and .
Molecular Biology of the Cell, 3r'~ ed., B.A. Alberts (ed.), Garland Publishing, New York (I994)). The fatty acid chains of the cardiolipin are prepared by the inventive method, whether short or long, also can be saturated or unsaturated.
[0036] The described methods can be used to prepare a variety of novel cardiolipin molecules. For example, the methods can be used to pxepare cardiolipin variants in pure form containing short or long fatty acid side chains. Preferred fatty acids range from carbon chain lengths of about C2 to C34, preferably between about C~ and about Ca4, and include tetranoic acid (C4:o), pentanoic acid (Cs:o), hexanoic acid (C6:o}, heptanoic acid (C~:o), octanoie acid (Cs:o), nonanoic acid (Cg:o)5 decanoic acid (Clo:o), wadecanoic acid (Cl:o), dodecanoie acid (Ciz:o), ~'idecanoie acid (Cls:o), tetradecanoic (myristic) acid (Ct4:o), pentadecanoic acid (Cis:o), hexadecanoic (pahnatic) acid (Cls:o), heptadecanoic acid (Cl~;o), octadecanoic (stearic) acid (Cis:o), nonadecanoic acid (Cl~:o), eicosanoic (arachidic) acid (Cao:o), heneicosanoic acid (Cm:o), docosanoic (behenic) acid (C2a:o), tricosanoic acid (C2s:o), tetracosanoic acid (Cz4;o},10-undecenoic acid (CII:z)a 11-dodecenoic acid (Cl2a), l.2-tridecenoic acid (C~3:~), myxistoleic acid (Cl4a), 10-pentadecenoic acid (Cisa), palmitoleic acid (Cilia), oleic acid (Cz$:~), linoleic acid (CiB:a), linolenic acid (Cisa), eicosenoic acid (Caoa), eicosdienoic acid (C2o:2}, eicosatrienoic acid (C2o:3), arachidonic acid (eis-5,8,11,14-eicosatetraenoic acid), and cis-5,8,11,1,17-eicosapentaenoic acid, among others. For ether analogs, the alkyl chain will also range from Cz to Cs~ pxeferably between about Ca. and about Cap.. Other fatty acid chains also can be employed as Rl andlor RZ
substituents.
Examples of such include saturated fatty acids such as ethanoic (or acetic) acid, propanoic (or propionic) acid, butanoic (or butyric} acid, hexacosanoic (or cerotic) acid, octacosanoic (or montanic) acid, triacontanoic (or melissic) acid, dotriacontanoic (or lacceroic) acid, tetratriacontanoic (or gheddic) acid, pentatriacontanoic (or ceroplastic) acid, and the like;
monoethenoic unsaturated fatty acids such as traps-2-butenoic (or crotonic) acid, cis-2-butenoic (or isocrotonoic) acid, 2-hexenoic (or isohydrosorbic) acid, 4-decanoic (or 5 obtusilic) acid, 9-decanoic (or caproleic) acid, 4-dodecenoic (or linderic) acid, 5-dodecenoic (or denticetic) acid, 9-dodecenoic (or lauroleic) acid, 4-tetradecenoic (or tsuzuic) acid, 5 tefiradecenoic (or physeteric) acid, 6-octadecenoic (or petroselenic) acid, tans-9-octadecenoic (or elaidic) acid, tans-11-octadecenoic (or vaccinic) acid, 9-eicosenoic (or gadoleic) acid, 11-eicosenoic (or gondoic) acid, 11-docosenoic (or cetoleic) acid, 13-10 decosenoic (or erucic) acid, 15-tetracosenoic (or nervonic) acid, 17-hexacosenoic (or ximenic) acid, 21-triacontenoic (or lumequeic) acid, and the like; dienoic unsaturated fatty acids such as 2,4-pentadienoic (or (3-vinylacrylic) acid, 2,4-hexadienoic~(or sorbic) acid, 2,4-decadienoic (or stillingic) acid, 2,4-dodecadienoic acid, 9,12-hexadecadienoic acid, cis-9, cis-12-octadecadienoic (or a-linoleic) acid, traps-9, tans-12-octadecadienoic (or linlolelaidic) acid, tans-l0,tans-12-octadecadienoic acid, 11,14-eicosadienoic acid, 13,I6-docosadienoic acid, 17,20-hexacosadienoic acid and the like; trienoic unsaturated fatty acids such as 6,10,14-hexadecatrienoic (or hiragonic) acid, 7,10, I 3-hexadecatrienoic acid, cis-6, cis-9- cis-12-octadecatrienoic (or y-linoleic) acid, tans-8, tans-10-tans-I2-octadecatrienoic (or (3-calendic) acid, cis-8, tans-10- cis-12-octadecatrienoic acid, cis-9, cis-12- cis-15-octadecatrienoic (or a-linolenic) acid, tans-9, tans-12- tabs-octadecatrienoic (or a-linolenelaidic) acid, cis-9, traps-11- tans-13-octadecatrienoic (or . a-eleostearic) acid, tans-9, tans-11- tans-13-octadecatrienoic (or (3-eleostearic) acid, cis-9, tans-11- cis-13-octadecatrienoic (or punicic) acid, 5,8,11-eicosatrienoic acid, 8,11,14-eicosatrienoic acid and the like; tetraenoic unsaturated fatty acids such as 4,8,11,14-hexadecatetraenoic acid, 6,9,12,15- hexadecatetraenoic acid, 4,8,12,15-octadecatetraenoic (or moroctic) acid, 6,9,12,15- octadecatetraenoic acid, 9,11,13,15-octadecatetraenoic (or a- or (3-parinaric) acid, 9,12,15,18-octadecatetraenoic acid, 4,8,12,16-eicosatetraenoic acid, 6,10,14,18-eicosatetraenoic acid, 4,7,10,13-docasatetraenoic acid, 7,10,13,16-docosatetraenoic acid, 8,12,16,19-docosatetraenoic acid and the like; penta- and hexa-enoic unsaturated fatty acids such as 4,8,12,15,18-eicosapentaenoic (or timnodonic) acid, 4,7,10,13,16-docosapentaenoic acid, 4,8,12,15,19-docosapentaenoic (or clupanodonic) acid, 7, I 0,13,16,19-docosapentaenoic, 4,7,10, 13,16,19-docosahexaenoic acid, 4,8,12,15,18,21-tetracosahexaenoic (or nisinic) acid and the like; branched-chain fatty acids such as 3-methylbutanoic (or isovaleric) acid, 8-methyldodecanoic acid, 10-methylundecanoic (or isolauric) acid, 11-methyldodecanoic (or isoundecylic) acid, 12-methyltxidecanoic (or isomyristic) acid, 13-methyltetradecanoic (or isopentadecylic) acid, 14-methylpentadecanoic (or isopalmitic) acid, 15-methylhexadecanoic, 10-methylheptadecanoic acid, 16-methylheptadecanoic (or isostearic) acid, 18-methylnonadecanoic (or isoarachidic) acid, 20-methylheneicosanoic (or isobehenic) acid, 22-methyltricosanoic (or isolignoceric) acid, 24-methylpentacosanoic (or isocerotic) acid, 26-methylheptacosanoic (or isomonatonic) acid, 2,4,6-trimethyloctacosanoic (or mycoceranic or mycoserosic) acid, 2-methyl-cis-2-butenoic(angelic)acid, 2-methyl-tans-2-butenoic (or tiglic) acid, 4-methyl-3-pentenoic (or pyroterebic) acid and the like.
[0037] The term 'hydroxyl protecting group' used herein the invention refers to the commonly used protecting groups disclosed by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
Such protecting groups include methyl ether, substituted methyl ethers including methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl ethers; substituted ethyl ethers like 1-ethoxyethyl, 1-methyl-1-benzyloxyethyl, allyl, propargyl; benzyl and substituted benzyl ethers includingp-methoxybenzyl, 3,4-dimethoxybenzyl, triphenylmethyl; silyl ethers including trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, diphenylmethylsilyl; esters including formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, benzoate, levulinylate and carbonates.
[0038] The term 'phosphate protecting group' used herein the invention refers to the commonly used protecting groups described by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
Such protecting groups include alkyl phosphates including methyl, ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl;
haloethyl phosphates including 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
[0039] The caxdiolipin molecules described herein and cardiolipins produced by the inventive method can be used in lipid formulations, such as liposomal compositions.
Complexes, emulsions and other formulations including the inventive cardiolipin also are within the scope of the present invention. Such formulations according to the present invention can be prepared by any suitable technique. The invention provides a method for preparing a liposome or other lipid composition, comprising preparing a cardiolipin or cardiolipin analogue as described herein and including the cardiolipin or cardiolipin analogue in a lipid formulation, such as a liposome. The invention also includes such lipid compositions including the inventive cardiolipin andlor cardiolipin analogues.
[0040] In addition to the inventive cardiolipin, the liposomal composition, complex, emulsion and the like can include other lipids. Thus, for example, the composition can include one or more phosphatidylcholines, such as, for example, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof. Alternatively or additionally, the composition can include one or more phosphatidylglycerols, such as dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof. Alternatively or additionally, the composition can include one or more sterols, such as cholesterol, derivatives of cholesterol, coprostanol, cholestanol, chalestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
Preferably, in addition to the cardiolipin or cardiolipin analogue, the composition includes a phosphatidylcholine, a sterol, and a tocopherol (e.g., a-tocopherol).
[0041] In addition to the cardiolipin and, optionally, other lipids, the composition also can include stabilizers, absorption enhancers, antioxidants, phospholipids, biodegradable polymers and medicinally active agents among other ingredients. In some embodiments, it is preferable for the inventive composition, especially liposomal composition, to include one or more targeting agents, such as carbohydrate or a protein or other ligand that binds to a specific substrate, for example, that recognize cellular receptors. The inclusion of such agents (such as a carbohydrate or one or more proteins selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands such as an antibody to a cellular receptor and mixtures thereof] can facilitate targeting a liposome to a predetermined tissue or cell type.
[0042] For medicinal use, the composition also can include one or more active agents.
A single active agent can be included, or a mixture of active agents (e.g., two or more active agents) can be included within the composition. Active agents (or "drugs") can be present in any suitable manner in the composition. For example, they can be complexed with the cardiolipin or cardiolipin analogue in the composition. Additionally, ox alternatively, one or more active agents can be entrapped within liposomes, when the composition is a liposomal composition.
[0043] Active agents which are compatible with the pxesent invention include, for example, agents which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synaptic sites, neuroeffector functional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, the alimentary and excretory systems, the histamine system and the central nervous system.
Suitable agents may be selected from, for example, proteins, enzymes, hormones, nucleotides (including sense and antisense oligonucleotides (see, e.g., U.S.
Patent 6,126,965), polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, .
polypeptides, steroids. Active agents can be analgesics, anesthetics, anti-arrythmic agents, antibiotics, antiallergic agents, antifungal agents, anticancer agents, anticoagulants, antidepressants, antidiabetic agents, anti-epilepsy agents, anti-inflammatory corticosteroids, agents for treating Alzheimers or Parkinson's disease, antiulcer agents, anti-protozoal agents, anxiolytics, thyroids, anti-thyroids, antivirals, anoretics, bisphosphonates, cardiac inotropic agents, cardiovascular agents, corticosteroids, diuretics, dopaminergic agents, gastrointestinal agents, hemostatics, hypercholesterol agents, antihypertensive agents (e.g., dihydropyridines), antidepressants, and cox-2 inhibitors, immunosuppressive agents anti-gout agents, anti-malarials, steroids, terpinoids, triterpines, retinouds;
anti-ulcer H2-receptor antagonists, hypoglycemic agents, moisturizers, cosmetics, anti-migraine agents, antimuscaxinic agents, antiinflammatory agents, such as agents for treating rheumatology, arthritis, psoriasis, inflammatory bowel disease, Crohn's disease; or agents for treating demyelinating diseases including multiple sclerosis, ophthalmic agents, vaccines (e.g., against pneumonia, hepatitis A, hepatitis B, hepatitis C, cholera toxin B
subunit, influenza virus, typhoid, plasmodium falciparun, diptheria, tetanus, HSV, tuberculosis, HIV,.SARS
virus, pordetela pertussis, measles, mumps and rubella vaccine (MMV), bacterial toxoids, vaccines virus, adenovirus, canary, polio virus, bacillus calmette guerin (BCG), klebsiella pneumonia, etc.), histamine receptor antagonists, hypnotics, kidney protective agents, lipid regulating agents, muscle relaxants, neuroleptics, neurotropic agents, opioid agonists and antagonists, parasympathomimetics, protease inhibitors, prostglandins, sedatives, sex hormones (e.g., estrogen, androgen), stimulants, sympathomimetics, vasodilators and xanthins and synthetic analogs of these species. The therapeutic agents can be nephrotoxic, such as cyclosporins and amphotericin B, or cardiotoxic, such as amphotericin B and paclitaxel. Exemplary anticancer agents include melphalan, chlormethine, extramustinephosphate, uramustine, ifosfamide, mannomustine, trifosfamide, streptozotocin, mitobronitol, mitoxantrone (see., e.g., published international patent application WO 02/32400), methotrexate, fluorouracil, cytarabine, tegafur, idoxide, taxanes (e.g., taxol, paclitaxel, etc., see published international patent application WO 00/01366), daunomycin, daunorubicin, bleomycin, amphotericin, carboplatin, cisplatin, paclitaxel, BCNU, vinca alkaloids (e.g., vincristine, vinorelbine (see, e.g., published international patent application WO 031018018), and the like) camptothecin and derivatives thereof (e.g., SN38 (see, e.g., published international patent application WO 021058622), irinotecan (see, e.g., published international patent application WO 03/030864), and the like), anthracyclines, antibodies, cytoxines, doxorubicin, etopside, cytokines, ribozymes, interferons, oligonucleotides and functional derivatives of the foregoing.
Additional examples of drugs which may be delivered according to the method include, prochlorperzine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzamphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperzine maleate, anisindone, diphenadione erythrityl tetranitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chloropromaide, tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-S-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17a-hydroxyprogesterone acetate, 19-norprogesterone, norgestrel, norethindrone, norethisterone, norethiederone, progesterone, norgesterone, norethynodrel, aspirin, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, diazepam, phenoxybenzamine, diltiazem, milrinone, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuinal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinolpril, enalapril, enalaprilat captopril, ramipril, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptyline, and imipramine. Further examples are proteins and peptides which.
include, but are not limited to, bone morphogenic proteins, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, digestive hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, GRF, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, LHRH agonists and antagonists, leuprolide, interferons (e.g., consensus interferon, interferon a-2a, interferon a-2b, a-, (3-, or y-interferons), interleukins, growth hormones such as human growth hormone and its derivatives such as methione-human growth hormone and des-phenylalanine human growth hormone, bovine growth hounone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors such as insulin-like growth factor, coagulation factors, pancreas hormone releasing factor, analogs and derivatives of these compounds, and pharmaceutically acceptable salts of these compounds, or their analogs or derivatives. The therapeutic agent can be a mixture of drugs or agents (e.g., two or more S agents) that can be beneficially co-administered in the liposome formulation.
[0044] Generally, liposomes can have a net neutral, negative or positive charge. For example, positive liposomes can be formed from a solution containing phosphatidylcholine, cholesterol, cardiolipin and enough stearylamine to overcome the net negative charge of cardiolipin. Negative liposomes can be formed from solutions containing phosphatidyl choline, cholesterol, andlor cardiolipin variants prepared by the methods described herein.
[0045] The liposomes of the present invention can be mufti or unilamellar vesicles depending on the particular composition and procedure to make them. Liposomes can be prepared to have substantially homogeneous sizes in a selected size range, such as about 1 micron or less, or about S00 nm or less, about 200nm or less, or about 100nm or less. One 1 S effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane.
[0046] The liposomal (or other lipid) composition can be in any desired form.
For example, for pharmaceutical use, the composition can be ready for administration to a patient. Alternatively, the composition can be in dried or lyophilized form.
Where the composition is dried or lyophilized, preferably the composition includes a cryoprotectant as well. Suitable cryoprotectants include, for example, sugars such as trehalose, maltose, lactose, sucrose, glucose, and dextran, with the most preferred sugars from a performance 2S point of view being trehalose and sucrose. Other more complicated sugars can also be used, such as, for example, aminoglycosides, including streptomycin and dihydrostreptomycin.
[0047] Any suitable method can be employed to form the liposomes. For example, lipophilic liposome-forming ingredients, such as phosphatidylcholine, a cardiolipin prepared by the methods described above, cholesterol and a-tocopherol can be dissolved or dispersed in a suitable solvent or combination of solvents and dried. Suitable solvents include any non-polar or slightly polar solvent, such as t-butanol, ethanol, methanol, chloroform, or acetone that can be evaporated without leaving a pharmaceutically unacceptable residue. Drying can be by any suitable means such as by lyophilization. The dehydration is typically achieved under vacuum and can take place either with or without 3S prior freezing of the liposome preparation. Hydrophilic ingredients can be dissolved in polar solvents, including water.
[0048] Mixing the dried lipophilic ingredients with the hydrophilic mixture can form liposomes. Mixing the polar solution with the dry lipid film can be by any means that strongly homogenizes the mixture. Vortexing, magnetic stirring and/or sonicating can effect the homogenization.
[0049] Where active agents (or a mixture of active agents) are included in the liposomes, the invention provides a method for retaining a drug in a liposome.
In accordance with the method, cardiolipin or cardiolipin analogue is prepared as described herein, and the caxdiolipin or cardiolipin analogue and a drug or drugs (e.g., an active agent a mixture of active agents) is included within a liposome. For example, active agents) can be dissolved or dispersed in a suitable solvent and added to the liposome mixture prior to mixing. Typically hydrophilic active agents will be added directly to the polar solvent and hydrophobic active' agents will be added to the nonpolar solvent used to dissolve the other ingredients but this is not required. The active agent could be dissolved in a third solvent or solvent mix and added to the mixture of polar solvent with the lipid film prior to homogenizing the mixture.
[0050] Liposomes can be coated with a biodegradable polymers such as sucrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene.
oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters.
[0051] Antioxidants can be included in the liposomal composition or other lipid composition. Suitable antioxidants include compounds such as ascorbic acid, tocopherol, and deteroxime mesylate.
[0052] Absorption enhancers can be included in the liposomal composition or other lipid composition. Suitable absorption enhancers include Na-salicylate-chenodeoxy cholate, Na deoxycholate, polyoxyethylene 9-lauryl ether, chenodeoxy cholate-deoxycholate and polyoxyethylene 9-lauryl ether, monoolein, Na tauro-24,25-dihydrofusidate, Na taurodeoxycholate, Na glycochenodeoxycholate, oleic acid, linoleic acid, linolenic acid. Polymeric absorption enhancers can also be included such as polyoxyethylene ethers, polyoxyethylene sorbitan esters, polyoxyethylene 10-lauryl ether, polyoxyethylene 16-lauryl ether, atone (1-dodecylazacycloheptane-2-one).
[0053] The inventive lipid (e.g.., liposomal) composition also can include one or more pharmaceutically acceptably excipients. For example, pharmaceutically suitable excipients include solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
The invention also includes pharmaceutical preparations in dosage units. This means that the preparations are in the form of individual parts, for example vials, syringes, capsules, pills, suppositories, or ampoules, of which the content of the liposome formulation of active agent corresponds to a fraction or a multiple of an individual dose. The dosage units can contain, for example, 1, 2, 3, or 4 individual doses, or 1/2, 1/3, or 1/4 of an individual dose.
An individual dose preferably contains the amount of active agent which is given in one administration and which usually corresponds to a whole, a half, a third, or a quarter of a daily dose.
[0054] Tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays can be suitable pharmaceutical preparations. Suppositories can contain, in addition to the liposomal active agent, suitable water-soluble or water-insoluble excipients. Suitable excipients are those in which the inventive liposomal active agent is sufficiently stable to allow for therapeutic use, for example polyethylene glycols, certain fats, and esters or mixtures of these substances.
Ointments, pastes, cream, and gels can also contain suitable excipients in which the liposomal active agent is stable. The composition also can be formulated for injection (egg., intravenously, interstitially, intratumorally, etc) by the inclusion of one or more excipients (e.g., buffered saline) suitable for injection.
[0055] The active agent or its pharmaceutical preparations can be administered intravenously, subcutaneously, locally, orally, paxenterally, intraperitoneally, and/or rectally or by direct injection into tumors or sites in need of treatment by such methods as are known or developed. Cardiolipin and cardiolipin-analog based formulations also can be administered topically, e.g., as a cream, skin ointment, dry skin softener, moisturizer, etc.
[0056] The invention provides for the use of the composition to prepare a medicament for the treatment of a disease. In this sense, the invention also provides a method for treating a human or animal disease. In accordance with the inventive method, the inventive composition is exposed to (administered to) a human or animal patient in need of such treatment. Where the composition also includes one or more active agents, the inventive method facilitates delivery of the active agents) to the patient.
[0057] The method can be used to administer one or more active agents. It is thought to be general for active agents that are stable in the presence of surfactants.
Hydrophilic active agents are suitable and can be included in the interior of the liposomes such that the liposome bilayer creates a diffusion barrier preventing it from randomly diffusing throughout the body. Hydrophobic active agents are thought to be particularly well suited for use in the present method because they not only benefit by exhibiting reduced toxicity but they tend to be well solubilized in the lipid bilayer of liposomes.
[0058] Suitable diseases for treatment will depend on the selection of active agents, such as described herein. However a preferred disease is cancer, in which instance, at least one active agent incorporated into the composition is an anticancer agent.
Chemotherapeutic agents are well suited for such use. Liposome formulations containing chemotherapeutic agents may be injected directly into the tumor tissue for delivery of the chemotherapeutic agent directly to cancer cells. In some cases, particularly after resection of a tumor, the liposome formulation can be implanted directly into the resulting cavity or may be applied to the remaining tissue as a coating. In cases in which the liposome formulation is administered after surgery, it is possible to utilize liposomes having larger diameters of about 1 micron since they do not have to pass through the vasculature.
[0059] In some embodiments, the method can be employed to treat diseases, disorders, or symptoms within patients even where the composition does not contain an active pharmaceutical agent other than cardiolipin. The invention provides for the use of cardiolipin to prepare a medicament to combat or treat such diseases, disorders, or symptoms. The invention further provides a method of treating such diseases, disorders, or symptoms within patients, and the effects of such diseases, disorders, or symptoms by administering to the patient a therapeutically effective amount of cardiolipin. Without being bound by any particular theory, it is believed that cardiolipin provides a beneficial antioxidant effect, which can alleviate the effects of many diseases, disorders, or symptoms.
Examples of conditions that can be treated in accordance with the method include, for example, age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders (e.g., acne, psoriasis, eczema, etc.). The method also can be employed to combat the effects of aging. For such use, the caxdiolipin can be formulated as a liposomal or non-liposomal formulation (e.g., an emulsion, cream, etc.) as discussed herein and can include, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
In use, the composition can be administered by any suitable route. For example, the composition can be administered dermally, intravenously, or by other desired route of administration. , [0060] The invention also is directed to methods of delivering active agents (or mixtures of active agents) to cells. The methods can be carried out by preparing liposomes that include active agents and cardiolipin variants/analogs as synthesized by the above disclosed methods. The liposomes are then delivered to a cell or cells, which can be ire vit~~o or i~ vivo, as desired. he vivo administration can be achieved as described herein or as otherwise known to those of ordinary skill. For in vitro use, delivery of the active agents) can be carried out by adding the composition (e.g., liposomes) to the cell culture medium, for example.
[0061] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
Example 1 Synthesis of Tetramyristoyl Cardioliuin lA. 2 Benzyl-1 3- bis [(1 2-dim~ristoyl-sn- lycero-3~phosphoryll~lycerol dibenzyl ester O O
R1 C-O O-C-Rl O
O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn OBn R1, R2 = myristoyl (Cl4:o chain) [0062] A solution of 1,2-dimyristoyl-sn-glycerol (10 g, 19.53 mmol), benzyl N, N
tetraisopropyl phosphoramidite (9.87 g, 29.29 mmol) and 1H-tetrazole (65 mL of 0.45 M
sol in acetonitrile, 29.29 mmol) in CH2C12 (125 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (1.18 g, 6.47 mmol) in CH2Cl2 (20 mL) was added followed by 1H- tetrazole (37.7 mL of 0.45 M sol in acetonitrile, 16.85 mmol) and stirred for 3 h. The reaction mixture was cooled to --40°C
and test-Butyl hydroperoxide (TBHP, 6.4 mL of 5-6 M sol in decane, 32.35 mmol) was added.
After stirring at --40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted mth CH2C12 (250 mL), washed f saturated aq NaZS03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 xnl,)} dried (Na2S04) and concentrated. The residue was purified on Si02 column (2:3 EtOAc: hexane) to give 6.68 g (69%) of protected cardiolipin as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.48.1H NMR
(CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J = 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
1B. 1 3 bis f(1 2 dim,~ristovl-sic- lyg~ cero-3~-phosphors]~lycerol diammonium salt (Tetramyristoyl cardiolipin) O O
R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, RZ = myristoyl (Cl4:o chain) [0063] A solution of protected cardiolipin from lA (2.5 g, 1.65 mmol) in tetrahydrofuran (40 mL) was hydrogenated at 50 psi over 10% Pd/C (900 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 4 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25~u filter and 5 precipitated with acetone to give tetramyristoyl (Cl4:o) cardiolipin (1.75 g, 83%) as a white solid. TLC (Si02) CHCl3/MeOH/NH40H (6.5:2.5:0.5) Rf~ O.SO.1H NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 80H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.06(bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1240.2 (M-2NH4++H~'), 1011.9 (M-2NH4+-10 RC00-), 619.9 (M-2NH4+)a-Example 2 _Synthesis of Tetralauroyl Cardiolinin 2A. 2 Benzyl-1 3- bis [(1 2-dilauroXl-sn- 1 cal-phosphors]glycerol dibenzyl ester O O
R~ C-O O-C-Rl O
O
O OBn O
O-P-O~O-P-O
i i OBn OBn Rl, RZ = lauroyl (Cla:o chain) [0064] Method 1: A solution of 1,2-dilauroyl-sn-glycerol (2.2 g, 4.82 mmol), benzyl N;
N tetraisopropyl phosphoramidite (1.95 g, 5.78 mmol) and 1H-tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) in CH2Cl2 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (352 mg, 1.92 mmol) in CH2C12 (10 mL) was added followed bylH- tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and Chloroperoxyperbenzoic acid (m-CPBA, 2.77 g, 9.64 mmol) was added in portions.
After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2C12 (150 mL), washed {saturated aq Na2S03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2S04) and concentrated. The residue was purified on Si02 column (2:3 EtOAc: hexane) to give 1.68 g (62%) of protected cardiolipin as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.44.1H NMR
(CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 64H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
[0065] Method 2: To a stirred solution of 1,2-Dilauroyl-s~-glycerol (5.0 g, 10.96 mmol) and tetrazole (29.2 mL of 0.45 M sol in acetonitrile, 13.15 mmol) in 40 mL
anhydrous CHZC12, dibenzyl diisopropyl phosphoramidite (4.54g, 13.15 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with100 mL of CHZC12 and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated iu vacuo and the oily residue (7.68 g) was dried in a desiccator for 8 h and used as such in the next reaction. A solution of this phosphite, 2-benzyloxy-l, 3-propanediol (0.8 g, 4.38 mmol), pyridine (4.43 mL, 54.77 mmol) and Et3N (7.63 mL, 54.77 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (5.25 g, 16.42 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (150 mL) and the organic layer~was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (NaaS04) and concentrated. The residue was purified on SiOa column (8%
acetone in CH2Cla) to give 3.8 g (62%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.44.
2B. 1 3 bis [(1 2-dilauroyl-sn-~1 cy ero-3)-phosphors]glycerol diammonium salt (Tetralauroyl cardiolipinl O O
R1 C-O O-C-Rl O
O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ O-NH4+
Ri, R2 = lauroyl (Clz:o chain) [0066] A solution of protected cardiolipin from 2A (1.5 g, 1.07 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25, filter and precipitated with acetone to give tetralauroyl (Cla:o) cardiolipin (1.0 g, 80%) as a white solid. TLC (SiOa) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.48.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 64H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 2.94 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).13C NMR 8 (CDC13, 125 MHz) 14.07, 22.67, 24.87, 24.93, 29.18, 29.22, 29.36, 29.37, 29.40, 29.57, 29.60, 29.66, 29.67, 29.69, 29.72, 31.91, 34.09, 34.28, 62.62, 63.57, 66.77, 69.47, 70.29, 173.25, 173.56. FTIR (ATR) 3207, 3035, 2956, 2918, 2850, 1737, 1467, 1378,1206,1092, 1067 cm 1. ESI-MS (negative), m/z 1150 (M-2NH4++Na~, 1127.4 (M-2NH4~, 1128.4 (M-2NH4++H~, 928.4 (M-2NH4+-RCOO-), 563.7 (M-2NH4~2-. Anal. Calculated for CS~H116N2Oi~Pz: C, 58.84; H, 10.05; N, 2.41:
P, 5.32.
Found: C, 57.75; H, 9.83; N, 2.34: P, 5.28.
Example 3 Synthesis of Tetralaurovl Cardioliuin [0067] In this method the tetralauroyl cardiolipin was synthesized by 2-cyanoethyl phosphoramidite.
3A. 2 Benwl 1 3 bis f(1 2-dilaurovl-sh-glycero-3~-phosphoryl]~lycerol dicyanoethyl ester O O
R~ C-O O-C-Rl O O
O OBn O
O-P-O~O-P-O
i i /O O\
NC Jr l'CN
Rl, R2 = lauroyl (Cla:o chain) [0068] To a mixture of 1,2-dilauroyl-sn-glycerol (1.74 g, 3.79 mmol) and N, N
diisopropylethylamine (545 mg, 4.22 mmol) in anhydrous ether (20 mL) under argon atmosphere was added 2-cyanoethyl diisopropylchlorophosphoramidite (1 g, 4.22mmo1).
The mixture was stirred at room temperature for lh, the separated disiopropylamine hydrochloride was filtered, and the filtrate was concentrated iu vacuo. The residue was as such used for the phosphorylation.
[0069] To a mixture of above phosphoramidite and 1H-tetrazole (9.4 mL of 0.45 M sol in acetonotrile, 4.22 mmol) in anhydrous CHaCl2 (30 mL) was added a solution of 2-benzyloxy 1,3-propanediol (312 mg, 1.71 mmol) in CH2C12 (5 mL). The reaction mixture was stirred at room temperature for 3 h and cooled to -40°C and m-CPBA
(1.36 g, 4.73 mmol was added in portions. After stirring at --40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2C12 (200 mL), washed f saturated aq NaaS03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2S04) and concentrated. The residue was purified on SiOz column (1:4 acetone:
CHaCl2) to give 1.48 g (70%) as colorless syrup. TLC (SiOa) EtOAc/ CH2C12 (1:3) Rf~ 0.48.1H
(CDCl3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.66 (m, 8H), 2.26-2.36 (m, 8H), 2.64-2.75 (m, 4H), 3.83-3.88 (m, 1H), 4.06-4.36 (m, 16H), 4.67 (s, 2H), 5.19-5.28 (m, 2H), 7.28-7.38 (m, SH).
3B. 1,3- bis 1f 1,2-dilauroyl-sn-~1 c~ero- 1-phosphorxll-, 2-~~l~.l~cerol diammonium salt O o R~ C-O O-C-Rl O
O
R2 C O O-C-Ra O OBn O
O-P-O~O-P-O
ONHq+ O'NH4+
Rl, R2 = lauroyl (Cla:o chain) A solution of the precursor from 3A (1.48 g, 1.2 mmol) and Et3N (1.66 mL, 12 mmol) in 10 mL acetonitrile was stirred overnight (TLC showed no remaining starting material) and evaporated to dryness. The residue was converted into ammonium salt by adding 2 mL of NHøOH and purified on SiO2 column (15% MeOH in CH2C12 containing 1% NH40H) to give 850 mg (60%) as colorless syrup that slowly solidified.iH NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.63 (m, 8H), 2.22-2.34 (m, 8H), 3.66-3.76 (m, 1H), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14-5.26 (m, 2H), 7.22-7.36 (m, SH), 7.49 (bs, 8H).
3C. 1 3 bis [(1 2-dilauroyl-sn-~lycero-3~phosphor~]glycerol diammonium salt (Tetralauroyl cardiolipinl O o R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = lauroyl (CIZ:o chain) [0070] A solution of protected cardiolipin from 3B (1.12 g, 0.89 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (450 mg) for 10 h. The catalyst was filtered off over celite bed and concentrated, the residue was dissolved in CHC13, filtered through a 0.25 ~, filter and precipitated with acetone to give tetralauroyl (Cia:o) cardiolipin (750 mg, 75%) cardiolipin as a white solid. TLC (Si02) column CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.48. The tetralauroyl cardiolipin prepared by this method described herein is identical to that of 2B in all aspects.
Example 4 Synthesis of Tetradecanovl Cardiolinin 4A. Synthesis of 1 2-Didecanoyl-3-benzyl-sh-~lycerol O
O-C-Rl O
ii O_C_R2 Bn0 R1, R2 = decanoyl (Clo:o chin) [0071] To an ice cooled solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (2.0 g, 10.97 mmol) and Et3N (6.89 mL, 49.36 mmol) in CH2Cl2 (30 mL) was added decanoyl chloride (5.1 mL, 24.69 mmol) dropwise over a period of 10 minutes followed by 4-(Dimethylamino)pyridine (DMAP, 268 mg, 2.19 mmol). The reaction mixture was stirred at room temperature for 12 h, diluted with CH2C12 (200 mL) washed successively with water (100 mL) and brine (100 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 cohunn (3% EtOAc in hexane) to give 4.5 g (83%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (9:1) Rf ~ 0.54. 1H NMR ~ (CDC13, 300 MHz) 0.87 (t, J
= 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J = 4.2 Hz, 2H), 4.18 (dd, J = 6.4 and 11.9 Hz, 1H), 4.34 (dd, J = 6.4 and 11.9 Hz, 1H), 4.51 (d, J =
12.2 Hz, 1H), 4.57 (d, J =12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
4B. 1 2-Didecanoyl-s~-gl cy erol O
O-C-Rl O
ii HO
R1, Ra = decanoyl (Clo:o chain) [0072] A solution of protected didecanoylglycerol from 4A (4.68 g, 9.55 mmol) in EtOH: EtOAc: AcOH (9:1:0.1) (40 mL) was hydrogenated at 40 psi over 10% PdIC
(600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DDG (3.52g, 92%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf~ 0.39.1H NMR ~ (CDCl3, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, Da0 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2. 3 5 (t, J = 7. 6 Hz, 2H) 3 .73 (t, J = 6.0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4.3 3 5 (dd, J= 5.8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
4C. 2-Benzyl 1 3 bis f(1 2-didecanoyl-sn-~lvcero-31-nhos~horyll~l_Ycerol dibenzyl ester O O
R~ C-O O-C-Rl O
ii R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn ~ OBn R1, R2 = decanoyl (Cio:o chain) [0073] A solution of 1,2-didecanoyl-sh-glycerol from 4B (3.52 g, 8.8 mmol), benzyl N, 10 N tetraisopropyl phosphoramidite (3.26 g, 9.68 mmol) and 1H-tetrazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) in CH2C12 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (712 mg, 3.9 mmol) in CH2C12 , (10 mL) was added followed by 1H- tetrazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and m-CPBA (5.06 g, 15 17.6 mmol) was added in portions. After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CHaCl2 (200 mL), washed f saturated aq Na2S03 (2 x 50 mL), saturated aq NaHC03 (2 x 50 mL), brine (2 x 50 xnL)}
dried (Na2S04) and concentrated. The residue was purified on SiOa column (2:3 EtOAc:
hexane) to give 3.21 g (64%) of protected cardiolipin as colorless syrup. TLC
(Si02) 20 hexane/EtOAc (3:2) Rf~ 0.44.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 48H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
4D. 1 3- bis [~1 2-didecano~l-s~- lycero-3~-phos~horyll~lvcerol diammonium salt O O
Rl-C-O O-C-Rl O
Ra C-O O-C-R2 O OH O
O-p-O~O-P-O
O'NH4+ ~O-NH~+
Rl, RZ = decanoyl (Clo:o chain) [0074] A solution of protected cardiolipin from 4C (1.5 g, 1.16 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25~u filter and concentrated to give tetradecanoyl (Clo:o) cardiolipin (1.0 g, 80%) as a semi solid. TLC
(SiO2) CHC13/MeOH/NHaOH (6.5:2.5:0.5) Rf~ 0.42.1H NMR ~ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 48H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.62 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1038 (M-2NH4++Na+), 1015 (M-2NH4+), 843.7 (M-2NH4+-RCOO-), 507.5 (M-2NH4+)a-.
Example 5 Synthesis of Tetraoctanovl Cardiolinin 5A. 1,2-Dioctano~-3-be., l-sn-glXcerol O
O-C-Rl O
~i Bn0 R1, R2 = octanoyl (CB:o chain) [0075] To a solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (4.Og, 21.95 mmol) in anhydrous pyridine (40 mL) was added octanoyl chloride (8.93 g, 54.87 mmol) dropwise over a period of 10 minutes followed by DMAP (267 mg, 2.19 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (300 mL) washed successively with water (100 mL), 1N HCl (2 x 100 mL) and brine (100 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (3% EtOAc in hexane) to give 7.3 g (75%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (9:1) Rf~ 0.52.1H NMR 8 (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.4 and 11.9 Hz, 1H), 4.34 (dd, J=
6.4 and 11.9 Hz, 1H), 4.51 (d, J= 12.2 Hz, 1H), 4.57 (d, J= 12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
SB. 1 2-Dioctanoyl-sn-glycerol O
O-C-Rl O
ii O-C-RZ
HO
R1, R2 = octanoyl (CB:o chain) [0076] A solution of protected dioctanoyl glycerol from SA (6.8 g, 15.66mmo1) in EtOH: EtOAc: AcOH (9:1:0.1) (30 mL) was hydrogenated at 40 psi over 10% PdIC
(900 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DOG (5.0, 93%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.31.1H NMR ~ (CDCl3, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, D20 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J
= 7.6 Hz, 2H) 3 .73 (t, J = 6. 0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4. 3 3 (dd, J = 5 . 8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
SC. 2-Benzyl-1 3- bis j(1 2-dioctanoXl-sn- 1 cy ero-3~phosphoryll~lycerol dibenzylester O O
R~ C-O ~ O-C-Rl O O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i OBn OBn R1, RZ = octanoyl (Cs:o chain) [0077] To a solution of 1,2-Dioctanoyl-sn-glycerol from SB (5.0 g, 14.53 mmol) and tetrazole (40.3 mI, of 0.45 M sol in acetonitrile, 18.16 mmol) in 50 mL
anhydrous CHaCl2, dibenzyl diisopropyl phosphoramidite (6.26g, 18.16 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of EtOAc and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ih vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0078] A solution of above phosphate, 2-benzyloxy-1, 3-propanediol (0.660 g, 3.63 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CHaCl2 (40 mL) was cooled to --40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL).
The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (10% acetone in CHZCIz) to give 2.72 g (64%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (3:2) Rf ~ 0.44.
1H NMR 8 (CDCl3, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 32H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, IH), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (rn, 4H), 5.15-5.18 (m, 2H), 7.28-IS 7.36 (m, 15H).
5D. 1,3- bas f(1,2-dioctanoyl-sv~-~lycero-31-bhosnhoryll-2-benzvl ~lvcerol diammonium salt _n_ Ra C O O-C-RZ
O OBn O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = octanoyl (CB;o chain) [0079] A solution of protected cardiolipin from SC (2.5 g, 2.12 mmol) in 2-butanone (15 mL) and sodium iodide (956 mg, 6.36 mmol) was refluxed at 90°C fox 3 h. The volatiles were evaporated and the residue was purified on SiOa column (20% methanol in CH2Cl2 containing 1 % of ammonia) to give 1.52 g (75%) of the product as colorless semisolid. TLC
(SiOz) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.53.1H NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.66-3.76 (m, 1H), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14-5.26 (m, 2H), 7.22-7.36 (m, 5H), 7.49 (bs, 8H).
SE: 13- bis f(1,2-dioctanovl-sn-gl_ycero-3~phosphoryl]glycerol diammonium salt o O
Ri C-O O-C-Rl O
ii R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, R2 = octanoyl (CB;o chain) [0080] A solution of protected cardiolipin from SD (1.5 g, 1.27 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25, filter and concentrated to give C~ cardiolipin (950 mg, 80%) as a semi solid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.43.1Ii NMR 8 (CDCl3, 500 MHz) 0.88 (t~
.I=
7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).
ESI-MS
(negative), m/z 925.7 (M-2NH4++Na++)-, 903.1(M-2NH4~, 760.6 (M-2NH4+-RCOO-), 451.2 (M-2NH4+)2-.
Example 6 Synthesis of Tetrahexanoyl Cardiolinin 6A. 1 2-Dihexanoyl-3-benzyl-sv~- lycerol O
O_C_Rl O
ii Bn0 Rl, RZ = hexanoyl (C6;o chain) [0081] To a solution of (R)-(+)-3-benzyloxy-1, 2-propanediol (2.6 g, 14.26 mmol) in anhydrous pyridine (30 mL) was added hexanoyl chloride (4.8 g, 35.67 mmol) dropwise over a period of 10 minutes followed by DMAP (175 mg, 1.42 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (200 mL) washed successively with water (100 mL), 1N HCl (2 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated. The residue was purified on SiOa column (3% EtOAc in hexane) to give 4.1 g (76%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (9:1) Rf~ 0.48.1H NMR S
(CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.4 and 11.9 Hz, 1H), 4.34 (dd, J=
6.4 and 11.9 Hz, 1H), 4.51 (d, J=12.2 Hz, 1H), 4.57 (d, J=12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, SH).
6B. 1 2-Dihexano~-sn-gl c O
O-C-R~
O
ii O-C-RZ
HO
R1, R2 = hexanoyl (C6:o chain) , [0082] A solution of protected dihexanoylglycerol from 6A (3.1 g, 8.2 mmol) in EtOH:
EtOAc: AcOH (9:1:0.1) (30 mL) was hydrogenated at 40 psi over 10% Pd/C (600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated;
the resulting glycerol (3.52g, 92%) was dried under high vacuum. TLC (Si02) hexane/EtOAc (3:2) Rf 0.34.1H NMR ~ (CDC13, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, D20 exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J=
7.6 Hz, 2H) 3 .73 (t, J = 6.0 Hz, 2H)), 4.22 (dd, J = 5 . 8 and 11.9 Hz, 1 H), 4.3 3 (dd, J = 5 . 8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
6C: 2 Benz~l 1 3 bis [(1 2 dihexanoyl-sn-glycero-31-phosphoryll ~lycerol dibenzyl ester R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OBn O
O-P-O~O-P-O
i i OBn OBn R1, R2 = hexanoyl (C6:o chain) [0083] To a solution of 1,2-Dihexanoyl-sn-glycerol from 6B (3.Sg, 13.19 mmol) and tetrazole (35.1 mL of 0.45 M sol in acetonitrile, 15.83 mmol) in 40 mL
anhydrous CH2C12, dibenzyl diisopropyl phosphoramidite (5.46g, 15.83 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of CHZCl2 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ire vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0084] A solution of above phosphite, 2-benzyloxy-1, 3-propanediol (0.957 g, 5.25 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL).
The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (10% acetone in CH2C12) to give 3.57 g (64%) of the product as colorless syrup. TLC (SiO~) hexane/EtOAc (3:2) Rf ~ 0.40.
1H NMR 8 (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, lOH), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
6D: 1.3- bis f(1,2-dihexanoyl-sn-~lycero-3~phosphoryll ~lycerol diammonium salt R~ C-O O-C-R~
O
R2_C_O O_C_Ra O OH O
O-P-O~O-P-O
ONH4+ ~-~4+
Rl, Rz = hexanoyl (C6:o chain) [0085] A solution of protected cardiolipin from 6C (1.5 g, 1.41 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHCl3, filtered through a 0.25, filter and concentrated to give C6 cardiolipin (940 mg, 81 %) as a semi solid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.36.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J=
7.0 Hz, 12H), 1.22-1.34 (m, 16H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H).
ESI-MS
(negative), mlz 813 (M-2NH4++Na~), 791 (M-2NH4++H+), 395 (M-2NH4+)z-.
Example 7 Synthesis of Tetraoleovl Cardiolipin (unsaturated) 7A. Cis 5 Levulinoyl-2-phenyl-1 3-dioxane O
O
O
O O
[0086] To a solution of cis-1,3-O-benzylideneglycerol (5.0 g, 27.74 mmol) in (80 mL) at 0°C, DCC (8.58 g, 41.61 mmol), DMAP (3,38 g, 27.74) and levulinic acid (4.0 g, 34.68 mmol) were sequentially added. The mixture was stirred for 24 hrs at room temperature. The separated urea was filtered, the filtrate was concentrated and purified by.
flash chromatography with 80% EtOAc/hexane as eluent to afford the product as a white solid (5.86 g, 76%). TLC (SiOa) hexane/EtOAc (l:l) Rf~ O.S1.1H NMR 8 (CDC13, MHz) 2.19 (s, 3H), 2.58-2.89 (m, 4H), 4.18 (dd, J= 12.0, 1.5 Hz, 2H), 4.25 (dd, J=12.0, 1.5 Hz, 2H), 4.71 (dd, J= 1.5, 1.5 Hz, 1H), 5.55 (s, 1H), 7.24-7.53 (m, SH).
7B. 2-Levulinoyl-1 3-propanediol O
O
O
HO~OH
[0087] A solution of protected glycerol 7A (5.8 g, 20.86 mmol) in EtOH: EtOAc (1:1) (100 mL) was hydrogenated at 50 psi over 10% PdIC (800 mg, 10%) for 8 h. The catalyst was filtered off over celite bed and concentrated; the resulting 2-levulinoyl glycerol was purified by flash chromatography with 6% MeOH/CHaCl2 as eluent to afford the product as a white solid (2.82 g, 70%). TLC (Si02) MeOH/CH2Cla (1:9) Rf ~ 0.31.1H NMR 8 (CDCl3, 300 MHz) 2.19 (s, 3H), 2.58 (dd, J= 6.0, 6.0 Hz, 2H), 2.80 (dd, J= 6.0, 6.0 Hz, 2H), 3.09.
(bs, 2H), 3.72-3.87 (m, 4H), 4.90 (q, J= 5.1 Hz).
7C. 2 Levulinoyl 1 3 bis f(1 2-dioleoyl-sh-gl cy ero-31-phosphoryll~lycerol dibenzyl ester O
R~ C-O O-C-Ri O O
R2_C_O O_C_R2 O OLev O
O-P-O~O-P-O
i i OBn OBn Ri, R2 = oleoyl (CiB;i chain) O
Lev =
O
[0088] To a solution of 1,2-Dioleoyl-sn-glycerol (l.Sg, 2.41 mmol) and tetrazole (8 mL
of 0.45 M sol in acetonitrile, 3.62 mmol) in 20 mL anhydrous CHZCIa, dibenzyl diisopropyl phosphoramidite (1.25g, 3.62 mmol) was added and stirred at room temperature for 2 h.
The contents were diluted with100 mL of CH2C12 and then washed with 5% aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated ih vacuo and the oily residue (2.08 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0089] A solution of above phosphite, 2-levulinoyl-1, 3-propanediol from 7B
(0.185 g, 0.96 mmol), pyridine (2 mL, 24.1 mmol) and Et3N (1.2 mL, 12.05 mmol) in CH2Cla (20 mL) was cooled to -40°C and pyridinium tribromide (1.15 g, 3.61 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (10 mL). The contents were diluted with EtOAc (100 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on Si02 column (5% acetone in CH2Cl2) to give 1.09 g (66%) of the product as colorless syrup. TLC (SiOa) hexane/EtOAc (1:2) Rf ~ 0.64.
iH NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 1.96-2.07 (m, 16H), 2.15 (s, 3H), 2.22-2.31 (m, 8H), 2.52-2.57 (m, 2H), 2.66-2.74 (m, 2H), 4.01-4.32 (m, 12H), 5.01-5.10 (m, SH), 5.15-5.18 (m, 2H), 5.28-5.39 (m, 8H), 7.28-7.39 (m, lOH).
7D. 1,3 bis f(1 2 dioleoyl sh slycero-31-phosnhoryll-2-levulinoyl ~lycerol diammonium salt R~ C-O O-C-Rl O O
R2_C_O O_C_R2 O OLev O
O-P-O~O-P-O
O-NH4+ ~-~4+
Rl, RZ = oleoyl (ClBa chain) [0090] A solution of protected cardiolipin from 7C (0.525 g, 0.324 mmol) in 2-butanone (8 mL) and sodium iodide (145 mg, 0.972 mmol) was refluxed at 90°C for 3 h.
The volatiles were evaporated and the residue was purified on SiOa column (10%
methanol in CHZCIa containing 1 % of ammonia) to give 240 mg (50%) of the product as colorless semisolid. TLC (Si02) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.63.1H NMR ~ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.96-2.07 (m, 16H), 2.18 (s, 3H), 2.23-2.35 (m, 8H), 2.52-2.59 (m, 2H), 2.71-2.79 (m, 2H), 3.83-4.04 (m, 6H), 4.12-4.23 (m, 4H), 4.31-4.39 (m, 2H), 5.01-5.09 (m, 1H), 5.17-5.26(m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1576.5 (M-2NH4++Na~', 1554 (M-2NH4~, 1272.2 (M-2NH4+-RCOO-), 776 (M-2NH4+)a .
7E. 1 3 bis j(1 2 dioleoyl sh ~lycero-3)-phosphor~l]glycerol diammonium salt (Synthesis of Tetraoleoyl Cardiolipin O O
Rl_C_O O_C_Rl O O
R2_C_O O_C_R2 O OH O
O-P-O~O-P-O
ONH4+ O~ -NHq.+
Rl, R2 = oleoyl (C18;1 chain) [0091] To a solution of lev- protected cardiolipin from 7D (140 mg, 0.088 mmol) in pyridine:acetic acid (3 mL, 4:1) was added hydazine (14 mg, 0.44 mmol) and stirred for 30 minutes. The volatiles were removed in rotavapor and the residue was purified on Si02 (10% methanol in CH2Cla containing 1% of ammonia) to give 80 mg (61%) of the product as colorless semisolid. TLC (Si02) (6.5:2.5:0.5) Rf~ O.SS.1H NMR 8 (CDCl3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.82 (bs, 1H), 1.96-2.07 (m, 16H), 2.23-2.35 (m, 8H), 3.83-3.94 (m, 7H), 4.12-4.23 (m, 4H), 4.33-4.39 (m, 2H), 5.17-5.23 (m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1478 (M-2NH4++Na )', 1456 (M-2NH4+), 1174.2 (M-2NH4+-RCOO'), 727.5 (M-2NHa~2'.
5 Cardiolinin Ether Analogs Example 8 Synthesis of Tetralauryl cardiolinin 8A. 2-Benz~l-1 3- bas [(1 2-dilaui I-;y sn-,~I" ce~ro-3_~ hn OSbhor~l~lycerol dibenzyl ester R10 ORl O OBn O
O-P-O~O-P-O
i i OBn OBn IO
R1, R2 = lauryl (Cla:o chain) (0092] To a stirred solution of 1,2-Dilauryl-s~-glycerol (3.0 g, 7.00 mmol) and tetrazole (19.5 mL of 0.45 M sol in acetonitrile, 8.76 mmol) in 40 mL anhydrous CH2C12, dibenzyl 1~5 diisopropyl phosphoramidite (3.02g, 8.76 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with100 mL of CH2Cla and then washed with 5%
aqueous NaHC03 (2 x 50 mL), brine (2 x SOmL), dried over Na2S04, concentrated in vacuo and the oily residue (4.5 g) was dried in a desiccator for 8 h and used as such in the next step reaction.
20 [0093] A solution of above phosphate, 2-benzyloxy-1, 3-propanediol (0.48 g, 2.67 mmol), pyridine (5.43 mL, 66.8 mmol) and Et3N (4.63 mL, 33.4 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (3.25 g, 10.02 mmol) was added at a time.
The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were 25 diluted with EtOAc (150 mL) and the organic layer was washed successively with aqueous 5% NaHC03 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2S04) and concentrated. The residue was purified on SiOa column (30% ethylacetate in hexane) to give 2.34 g (67%) of the product as colorless syrup. TLC (Si02) hexane/EtOAc (3:2) Rf 0.47. IH NMR 8 (CDC13, 300 MHz) 0.88 (t, J= 6.6 Hz, 12H), 1.22-1.34 (m, 72H), 1.47-30 1.56 (m, 8H), 3.35-3.58 (m, 14H), 3.72-3.78 (m, 1H), 3.95-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.07 (rn, 4H), 7.26-7.34 (m, 15H).
8B: 1 3 bis [(1 2 dilaur ly sh glycero-3~~hosphor~]glycerol diammonium salt (Tetralauryl Cardioliuinl O OH O
O-P-O~O-P-O
O'NH4+ O-NH4+
Rl, R2 = lauryl (Cla:o chain) [0094] A solution of protected cardiolipin from 8A (650 mg, 0.48 mmol) in tetrahydrofuran (20 mL) was hydrogenated at 50 psi over 10% PdIC (200 mg) for 6 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25, filter and precipitated with acetone to give Ci2 cardiolipin (400 mg, 75%) as a white semisolid. TLC
(Si02) CHCl3/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.39.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 72H), 1.52-1.66 (m, 8H), 3.39-3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.59 (bs, 8H). ESI-MS (negative), m/z 1094.1 (M-2NH4++Na ), 1072.0 (M-2NH4++H+), 535.5 (M-2NH4~2-.
Example 9 Synthesis of Tetrahexyl Cardiolipin 9A. 2 Benzyl 1 3 bis j(1 2-dihexvl-s~~lycero-3)-phosphorvll~lvcerol dibenzyl ester Ra0 ORa O OBn O
O-P-O~O-P-O
OBn OBn R1, R2 = hexyl (C6;o chain) [0095] The title compound was prepared according to the method described in example 8A. TLC (Si02) hexane/EtOAc (3:2) Rf ~ 0.39.1H NMR 8 (CDCl3, 300 MHz) 0.88 (t, J=
6.6 Hz, 12H), 1.22-1.37 (m, 24H), 1.47-1.58 (m, 8H), 3.34-3.58 (m, 14H), 3.72-3.78 (m, 1H), 3.94-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.08 (m, 4H), 7.26-7.34 (m, 15H).
9B: 1 3 bis ((1 2 dihex~l_ sh ~lycero 31-phosphorXll~lyc~ opium salt (Tetrahexvl Cardiolipinl R10 ORl O OH O
O-P-O~O-P-O
O-NHq+ ~-NH4+
Rl, R2 = hexyl (C6;o chain) [0096] The title compound was prepared according to the method described in example 8B.TLC (SiOa) CHC13/MeOH/NH40H (6.5:2.5:0.5) Rf~ 0.31.1H NMR 8 (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 24H), 1.50-1.61 (m, 8H), 1.88 (bs, 1H), 3.39-3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.69 (bs, 8H).
Example 10 [0097] This example demonstrates preparation of a cardiolipin-containing liposome composition of the invention. Small unilamellar vesicles are formed by mixing 19.1 ~umole of cardiolipin, produced according to the methods described herein, 96.2 ~,mol of phosphatidyl choline and 64.6 ~,mol of cholesterol. After thorough stirring, the mixture is evaporated to dryness in a 50 ml round-bottom flask using a rotary evaporator.
The subsequent dried lipid film is resuspended in 10 ml sterile non-pyrogenic water. After a 30 minute swelling time, the resulting suspension is sonicated in a fixed temperature bath at 25 °C for 15 minutes. The preparation of liposomes is then lyophilized with trehalose.
[0098] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
(0099] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having,"
"including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00100] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments might become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subj ect matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
References 1. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadgopoulos, D.
Pharm. Rev. ,1999, 51, 691-743 .
2. Ramirez, F.; Ioannou, P. V.; Marecek, J. F.; Golding, B. T.; Dodd, G. H.
Synthesis.
1976,11, 769-770.
3. Duralski, A. A.; Spooner, P. J. R.; Watts, A. Tetrahedron Lett. 1989, 30, 3585-3588.
4. Duralski, A. A.; Spooner, P. J. R.; Rankin, S. E.; Watts, A. Tetrahedron Lett.1998, 39, 1607-1610.
5. Saunders, R. M.; Schwaxz. J. Am. Chem. Soc. 1966, 88, 3844-3847.
6. Mishina, I. M.; Vasilenko, A. E.; Stepanov, A.E.; Shvets, V. I. Bioorg.
Khinz. 1985, 11, 992-994.
7. Stepanov, A.E.; Makarova, I. M.; Shvets, V. I. Zh. Org., Khim. 1984, 20, 985-988.
8. DeHaas, G.H.; Bonsen, P.P.M.; VanDeenen, L.L.M. Biochim. Biophys.
Acta,1966, 116: 114-124.
9. moue, K.; Suhara, Y.; Nojima, S. Chem. Pharm. Bull.,1963, 1150-1156.
10. Browne, J. E.; Driver, M. J.; Russet, J. C.; Sammes, P. G. J. Chem. Soc.
Pe~ki~
Tr~ans. 1. 2000, 653-657.
11. Watanabe, Y.; Inada, E.; Jinno, M.; Ozaki, S. Tetr~ahedro~c Lett. 1993, 34, 497-500.
12. Watanabe, Y.; Hirofuji, H.; Ozaki, S. Tetrahedron Lett. 1994, 35, 123-124.
13. Watanabe, Y.; Nakamura, T.; Mitsumoto, H. Tetrahedron Lett. 1997, 38, 7407-7410.
14. Watanabe, Y.; Ishikawa, H. Tetrahedrov~ Lett. 2000, 41, 8509-8512.
15. Watanabe, Y.; Nakatomi, M. Tetrahedrov~ Lett. 1998, 39, 1583-1586.
16. Chen, J.; Feng, L.; Prestwich, G. D. J. Org. Chem. 1998, 63, 6511-6522.
17. Lindberg, J.; Ekeroth, J.; Konradsson, P. J. Org. Chem. 2002, 67, 194-199.
18. Chen, J.; Profit, A. A.; Prestwich, G. D. J. Or~g. Chem. 1996, 61, 6305-6312.
19. Prestwich, G. D. Acc. Chem. Res. 1996, 29, 503-513.
20. Gu, Q. M.; Prestwich, G. D. J. Org. Chem. 1996, 61, 8642-8647.
21. Murakami, K.; Molitor, E. J.; Liu, H.W. J. Org. Chem.1999, 64, 648-651.
22. Prestwich, G. D.; Marecek, J. F.; Mourey, R. J.; Thiebert, A.B.; Ferris, C. D.;
Danoff, S. K.; Snyder, S. H. J. Am. Chem. Soc. 1991,113, 1822-1825.
Danoff, S. K.; Snyder, S. H. J. Am. Chem. Soc. 1991,113, 1822-1825.
23. Dreef, C. E.; Elie, C. J. J.; Hoogerhout, P.; van der Marel, G. A.; van Boom, J. H.
Tetrahedron Lett. 1988, 29, 6513-6516.
Tetrahedron Lett. 1988, 29, 6513-6516.
24. moue, K.; Nojima, S. Chem. Pharm. Bull. 1968, 16, 76-81.
25. Ioannou, P. V.; Marecek, J. F. Chem. Chrov~. 1986, I S, 205-220.
26. Ramirez, F.; Ioannou, P. V.; Marecek, J. F.; Dodd, G. H.; Golding, B. T.
Tet~ahedroh. 1977, 33, 599-608.
Tet~ahedroh. 1977, 33, 599-608.
27. Mishina, I. M.; Vasilenko, A. E.; Stepanov, A.E.; Shvets, V. I. Bioorg.
Khim. 1987, 13, 1110-1115.
Khim. 1987, 13, 1110-1115.
28. Keana, J. F. W.; Shimiju, M.; Jernstedt, K. K. J. O~g. Chem. 1986, 51, 2297-2299.
29. Chevallier, J.; Sakai, N.; Robert, F.; Kobayashi, T.; Gruenberg, J.;
Matile, S. Org.
Lett. 2000, 2, 1859-1861.
Matile, S. Org.
Lett. 2000, 2, 1859-1861.
30. Wilk, A.; Srinivasachar, K.; Beaucage, S. J. O~g. Chem. 1997, 62, 6712-6713.
31. Moriguchi, T.; Yanagi, T.; Kunimori, M.; Wada, T.; Sekine, M. J. O~g.
Chem.
2000, 65, 8229-8238.
Chem.
2000, 65, 8229-8238.
Claims
What is claimed is:
1. A method for preparing a cardiolipin analogue of formulas I, II or III
comprising reacting an alcohol of the formula VIII
with one or more phosphoramidite reagents and 2-O-protected glycerol or 2-O-subsituted glycerol in the presence of an acid catalyst, wherein, in Formulas I, II, III, or VIII
Y1 and Y2 are the same or different and are-O-C(O)-, -O-, -S-, or-NH-C(O)-;
R1 and R2 are the same or different and are H, C2 to C34 saturated or unsaturated alkyl group;
R3 is (CH2)n and n = 0 - 15;
R4 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, a peptide, dipeptide, polypeptide, protein, carbohydrate, heterocyclic, nucleoside, polynucleotide;
R5 is a linker comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy, polyalkyloxy, a peptide, dipeptide, polypeptide, protein, carbohydrate;
X is hydrogen or a non-toxic cation.
10. The method of claim 9, wherein the cardiolipin comprises fatty acids having between 4 and 12 carbons.
11. The method of claims 1-8, wherein the cardiolipin comprises long-chain fatty acids having between 14 and 34 carbons.
12. The method of claim 11, wherein the cardiolipin comprises fatty acids having between 14 and 24 carbons.
13. The method of claims 1-12, wherein the cardiolipin is saturated and/or unsaturated.
14. A method for preparing a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13 and including the cardiolipin or cardiolipin analogue in a liposome.
15. A method for retaining a drug in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a drug in a liposome.
16. A method for retaining drugs in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a mixture of drugs in a liposome.
17. The method of claim 16, wherein the mixture comprises two or more drugs.
18. A liposomal composition prepared by the method of any of claims 14-17.
19. The composition of claim 18, which comprises unilamellar vescicles, multilamellar vesicles, or mixtures thereof.
20. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 1 micron or less.
21. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 500 nm or less.
22. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 200 nm or less.
23. The composition of any of claims 18-19, wherein the liposomes have a diameter of about 100 nm or less.
24. The composition of any of claims 18-24, which further comprises a pbosphatidylcholine, a sterol, and a cocopherol.
25. The composition of any of claims 18-24, which further comprises a phosphatidylcholine selected from the group consisting of dimyristoylphosphatidylcholine, distearoylphospharidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.
26. The composition of any of claims 18-25, which further comprises a phosphatidylglycerol, selected from the group consisting of dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof.
27. The composition of any of claims 18-26, which further comprises a sterol selected from the group consisting of cholesterol, derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
28. The composition of any of claims 18-27, further comprising one or more targeting agents.
29. The composition of claim 28, wherein the targeting agent is a protein.
30. The composition of claim 29, wherein the protein is selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands, and mixtures thereof.
31. The composition of any of claims 18-30, in lyophilized form.
32. The composition of claim 31, further comprising a cryoprotectant.
33. The composition of any of claims 18-32, further comprising a ligand.
34. The liposome composition of claim 33, wherein the ligand is an antibody or a ligand for a cellular receptor.
35. The composition of any of claims 18-34, which further comprises a pharmaceutically acceptable excipient.
36. The composition of any of claims 18-38, further comprising an active agent, 37. The composition of any of claims 18-36, further comprising a mixture of active agents.
38. The composition of any of claim 37, wherein said mixture comprises two or more active agents.
39. The composition of any of claims 18-38, wherein at least one of said active agents is complexed with cardiolipin or cardiolipin analogue.
40. The composition of any of claims 18-39, wherein at least one of said active agents is entrapped within liposomes.
41. The use of a composition of any claims 36-40, to prepare a medicament for the treatment of a disease.
42. The use according to claim 41, wherein the disease is cancer.
43. A method of delivering an active agent or mixture of active agents to cell, comprising preparing a composition according to any of claims 14-17 and exposing the composition to a cell.
44. The method of claim 43, wherein the cell is in vitro.
45. The method of claim 43, wherein the cell is in vivo.
46. A method of treating a human or animal disease, comprising preparing a composition according to any of claims 14-17 and exposing the composition to a human or animal in need thereof such that the active agent is delivered to the human or animal patient.
47. The method of claim 46, wherein the disease is cancer and at least one of said active agents is an anticancer agent.
48. Use of cardiolipin to prepare a medicament to combat aging.
49. Use of cardiolipin to prepare a medicament to combat a mammalian disease.
50. The use according to claim 49, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
51. The use according to any of claims 48-50, wherein the cardiolipin is in the form of a liposomal composition.
52. The use according to any of claims 48-51, wherein the cardiolipin is other than in the form of a liposomal composition.
53. A method of treating the effects of aging in a patient, comprising administering the patient a therapeutically effective amount of cardiolipin such that the effects of aging are combated in said patient.
54. A method of treating a mammalian disease, comprising administering to a patient in need of treatment an amount of cardiolipin sufficient to treat said disease.
55. The method of claim 54, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
56. The method of any of claims 53-55, wherein the composition includes, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
57, The method of any of claims 53-56, wherein the composition is administered dermally.
58. The method of any of claims 53-56, wherein the composition is administered intravenously.
59. The method of any of claims 53-58, wherein the composition is other than a liposomal composition.
1. A method for preparing a cardiolipin analogue of formulas I, II or III
comprising reacting an alcohol of the formula VIII
with one or more phosphoramidite reagents and 2-O-protected glycerol or 2-O-subsituted glycerol in the presence of an acid catalyst, wherein, in Formulas I, II, III, or VIII
Y1 and Y2 are the same or different and are-O-C(O)-, -O-, -S-, or-NH-C(O)-;
R1 and R2 are the same or different and are H, C2 to C34 saturated or unsaturated alkyl group;
R3 is (CH2)n and n = 0 - 15;
R4 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, a peptide, dipeptide, polypeptide, protein, carbohydrate, heterocyclic, nucleoside, polynucleotide;
R5 is a linker comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy, polyalkyloxy, a peptide, dipeptide, polypeptide, protein, carbohydrate;
X is hydrogen or a non-toxic cation.
10. The method of claim 9, wherein the cardiolipin comprises fatty acids having between 4 and 12 carbons.
11. The method of claims 1-8, wherein the cardiolipin comprises long-chain fatty acids having between 14 and 34 carbons.
12. The method of claim 11, wherein the cardiolipin comprises fatty acids having between 14 and 24 carbons.
13. The method of claims 1-12, wherein the cardiolipin is saturated and/or unsaturated.
14. A method for preparing a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13 and including the cardiolipin or cardiolipin analogue in a liposome.
15. A method for retaining a drug in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a drug in a liposome.
16. A method for retaining drugs in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a mixture of drugs in a liposome.
17. The method of claim 16, wherein the mixture comprises two or more drugs.
18. A liposomal composition prepared by the method of any of claims 14-17.
19. The composition of claim 18, which comprises unilamellar vescicles, multilamellar vesicles, or mixtures thereof.
20. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 1 micron or less.
21. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 500 nm or less.
22. The liposome composition of any of claims 18-19, wherein the liposomes have a diameter of about 200 nm or less.
23. The composition of any of claims 18-19, wherein the liposomes have a diameter of about 100 nm or less.
24. The composition of any of claims 18-24, which further comprises a pbosphatidylcholine, a sterol, and a cocopherol.
25. The composition of any of claims 18-24, which further comprises a phosphatidylcholine selected from the group consisting of dimyristoylphosphatidylcholine, distearoylphospharidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.
26. The composition of any of claims 18-25, which further comprises a phosphatidylglycerol, selected from the group consisting of dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof.
27. The composition of any of claims 18-26, which further comprises a sterol selected from the group consisting of cholesterol, derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
28. The composition of any of claims 18-27, further comprising one or more targeting agents.
29. The composition of claim 28, wherein the targeting agent is a protein.
30. The composition of claim 29, wherein the protein is selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands, and mixtures thereof.
31. The composition of any of claims 18-30, in lyophilized form.
32. The composition of claim 31, further comprising a cryoprotectant.
33. The composition of any of claims 18-32, further comprising a ligand.
34. The liposome composition of claim 33, wherein the ligand is an antibody or a ligand for a cellular receptor.
35. The composition of any of claims 18-34, which further comprises a pharmaceutically acceptable excipient.
36. The composition of any of claims 18-38, further comprising an active agent, 37. The composition of any of claims 18-36, further comprising a mixture of active agents.
38. The composition of any of claim 37, wherein said mixture comprises two or more active agents.
39. The composition of any of claims 18-38, wherein at least one of said active agents is complexed with cardiolipin or cardiolipin analogue.
40. The composition of any of claims 18-39, wherein at least one of said active agents is entrapped within liposomes.
41. The use of a composition of any claims 36-40, to prepare a medicament for the treatment of a disease.
42. The use according to claim 41, wherein the disease is cancer.
43. A method of delivering an active agent or mixture of active agents to cell, comprising preparing a composition according to any of claims 14-17 and exposing the composition to a cell.
44. The method of claim 43, wherein the cell is in vitro.
45. The method of claim 43, wherein the cell is in vivo.
46. A method of treating a human or animal disease, comprising preparing a composition according to any of claims 14-17 and exposing the composition to a human or animal in need thereof such that the active agent is delivered to the human or animal patient.
47. The method of claim 46, wherein the disease is cancer and at least one of said active agents is an anticancer agent.
48. Use of cardiolipin to prepare a medicament to combat aging.
49. Use of cardiolipin to prepare a medicament to combat a mammalian disease.
50. The use according to claim 49, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
51. The use according to any of claims 48-50, wherein the cardiolipin is in the form of a liposomal composition.
52. The use according to any of claims 48-51, wherein the cardiolipin is other than in the form of a liposomal composition.
53. A method of treating the effects of aging in a patient, comprising administering the patient a therapeutically effective amount of cardiolipin such that the effects of aging are combated in said patient.
54. A method of treating a mammalian disease, comprising administering to a patient in need of treatment an amount of cardiolipin sufficient to treat said disease.
55. The method of claim 54, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
56. The method of any of claims 53-55, wherein the composition includes, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
57, The method of any of claims 53-56, wherein the composition is administered dermally.
58. The method of any of claims 53-56, wherein the composition is administered intravenously.
59. The method of any of claims 53-58, wherein the composition is other than a liposomal composition.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41927702P | 2002-10-16 | 2002-10-16 | |
US60/419,277 | 2002-10-16 | ||
US42928502P | 2002-11-26 | 2002-11-26 | |
US60/429,285 | 2002-11-26 | ||
US43865903P | 2003-01-07 | 2003-01-07 | |
US60/438,659 | 2003-01-07 | ||
US46733103P | 2003-05-02 | 2003-05-02 | |
US60/467,331 | 2003-05-02 | ||
USPCT/US03/13917 | 2003-05-04 | ||
PCT/US2003/013917 WO2004062569A2 (en) | 2003-01-07 | 2003-05-04 | Cardiolipin compositions their methods of preparation and use |
USPCT/US03/16412 | 2003-05-23 | ||
PCT/US2003/016412 WO2003099830A2 (en) | 2002-05-24 | 2003-05-23 | Cardiolipin compositions, methods of preparation and use |
PCT/US2003/027806 WO2004039817A1 (en) | 2002-10-16 | 2003-09-05 | Cardiolipin molecules and method of synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2502285A1 true CA2502285A1 (en) | 2004-05-13 |
Family
ID=32234368
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002502285A Abandoned CA2502285A1 (en) | 2002-10-16 | 2003-09-05 | Cardiolipin molecules and method of synthesis |
CA002501990A Abandoned CA2501990A1 (en) | 2002-10-16 | 2003-10-16 | Cationic cardiolipin analogs and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002501990A Abandoned CA2501990A1 (en) | 2002-10-16 | 2003-10-16 | Cationic cardiolipin analogs and use thereof |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP1556392A1 (en) |
JP (2) | JP2006510733A (en) |
AU (2) | AU2003268478A1 (en) |
CA (2) | CA2502285A1 (en) |
EA (2) | EA200500659A1 (en) |
HK (1) | HK1080087A1 (en) |
WO (2) | WO2004039817A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US20080286351A1 (en) * | 2004-06-29 | 2008-11-20 | Ahmad Moghis U | Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof |
MX2007005591A (en) * | 2004-11-08 | 2008-02-12 | Neopharm Inc | Synthesis of cardiolipin analogues and uses thereof. |
WO2006113679A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
WO2007014150A2 (en) * | 2005-07-22 | 2007-02-01 | Neopharm, Inc. | Method of administering liposomes containing oligonucleotides |
CA2631677C (en) | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
WO2007065017A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Oligonucleotide cationic liposomal delivery system |
MX2008010826A (en) * | 2006-02-24 | 2009-03-02 | Neopharm Inc | Method and process for preparing cardiolipin. |
CA2737025C (en) * | 2008-09-27 | 2012-09-04 | Jina Pharmaceuticals, Inc. | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
CN104334185B (en) * | 2012-04-11 | 2016-12-28 | 利博恩科技有限公司 | The liposome of the oligopeptide fragments containing myelin basic protein, for treating pharmaceutical composition and the method for multiple sclerosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2113606A (en) * | 1934-05-24 | 1938-04-12 | Alba Pharmaceutical Company In | Quaternary ammonium compounds |
US6461637B1 (en) * | 2000-09-01 | 2002-10-08 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
ES2296419T3 (en) * | 1998-11-12 | 2008-04-16 | Invitrogen Corporation | TRANSFECTION REAGENTS. |
ATE283254T1 (en) * | 1999-05-28 | 2004-12-15 | Vical Inc | CYTOFECTIN DIMERS AND METHOD FOR USE THEREOF |
-
2003
- 2003-09-05 EP EP03749443A patent/EP1556392A1/en not_active Withdrawn
- 2003-09-05 EA EA200500659A patent/EA200500659A1/en unknown
- 2003-09-05 JP JP2005501873A patent/JP2006510733A/en active Pending
- 2003-09-05 CA CA002502285A patent/CA2502285A1/en not_active Abandoned
- 2003-09-05 WO PCT/US2003/027806 patent/WO2004039817A1/en not_active Application Discontinuation
- 2003-09-05 AU AU2003268478A patent/AU2003268478A1/en not_active Abandoned
- 2003-10-16 WO PCT/US2003/033099 patent/WO2004035523A1/en not_active Application Discontinuation
- 2003-10-16 EP EP03809159A patent/EP1558562A1/en not_active Withdrawn
- 2003-10-16 JP JP2005501473A patent/JP2006503112A/en active Pending
- 2003-10-16 CA CA002501990A patent/CA2501990A1/en not_active Abandoned
- 2003-10-16 EA EA200500661A patent/EA200500661A1/en unknown
- 2003-10-16 AU AU2003277445A patent/AU2003277445A1/en not_active Abandoned
-
2005
- 2005-12-30 HK HK05112200.6A patent/HK1080087A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003268478A1 (en) | 2004-05-25 |
EP1556392A1 (en) | 2005-07-27 |
AU2003277445A1 (en) | 2004-05-04 |
CA2501990A1 (en) | 2004-04-29 |
WO2004039817A1 (en) | 2004-05-13 |
EA200500659A1 (en) | 2005-10-27 |
HK1080087A1 (en) | 2006-04-21 |
WO2004035523B1 (en) | 2004-08-26 |
JP2006503112A (en) | 2006-01-26 |
EA200500661A1 (en) | 2005-10-27 |
JP2006510733A (en) | 2006-03-30 |
WO2004035523A1 (en) | 2004-04-29 |
WO2004039817A9 (en) | 2004-07-22 |
EP1558562A1 (en) | 2005-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050266068A1 (en) | Cardiolipin molecules and methods of synthesis | |
US20050181037A1 (en) | Cardiolipin compositions their methods of preparation and use | |
US20050277611A1 (en) | Cationic cardiolipin analoges and its use thereof | |
Eibl | Phospholipids as functional constituents of biomembranes | |
US9637515B2 (en) | Guggulphospholipid methods and compositions | |
US20080286351A1 (en) | Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof | |
JPH08504439A (en) | Lipid derivatives of phosphonoic acids for liposome incorporation and methods of use | |
CA2502285A1 (en) | Cardiolipin molecules and method of synthesis | |
US20120009246A1 (en) | Phospholipid-analogous compounds | |
WO2006048017A1 (en) | Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof | |
US20080300418A1 (en) | Synthesis of Cardiolipin Analogues and Uses Thereof | |
AU754862B2 (en) | Use of bisphosphonates for the prevention and treatment of infectious processes | |
CN1714095A (en) | Cardiolipin molecules and method of synthesis | |
WO2007100808A2 (en) | Method and process for preparing cardiolipin | |
WO2004062569A2 (en) | Cardiolipin compositions their methods of preparation and use | |
WO2004060899A1 (en) | Phospholipid derivatives and process for the production there | |
CN1714094A (en) | Cardiolipin compositions their methods of preparation and use | |
JP2003522203A (en) | Non-naturally occurring nucleic acid compositions, their use for preparing formulations useful for transfecting nucleic acids into cells, and applications | |
WO2024019770A1 (en) | Methods of making ionizable lipids and lipid nanoparticles for mrna delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |